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ABSTRACT 
NON-REDUNDANT AND CRITICAL ROLES FOR LEUKOTRIENE B4 RECEPTORS, 
BLTl AND BLT2, IN MOUSE MODELS OF INFLAMMATORY ARTHRITIS 
Steven Mathis 
April 4, 2007 
Inflammation is now recognized as an important factor in several age-related 
diseases such as arthritis, atherosclerosis, multiple sclerosis and diabetes. In each case, 
sub-clinical chronic inflammation occurs over years and leads to progressive destruction 
of the tissue until the symptoms become clinically apparent. Eicosanoids such as 
prostaglandins and leukotrienes play an important role in inflammation. Among these, 
leukotriene B4 (L TB4) has had a long history of being associated with numerous 
inflammatory diseases. A high affinity receptor for L TB4, L TB4 receptor 1 (BL Tl) has 
been well-characterized in human and murine tissues. While the molecular mechanisms 
remain unclear, its importance in diverse inflammatory diseases was demonstrated in 
mice lacking BL Tl. More recently, a second highly conserved low affinity LTB4 
receptor, L TB4 receptor 2 (BL T2) was identified, but its functional significance remains 
completely unknown. Both BLTI and BLT2 are seven-transmembrane G protein coupled 
receptors transducing signals through heterotrimeric G-proteins. 
Chapter II of this thesis describes the generation and characterization of 
monoclonal antibodies to BLTl. Immunization of BL Tl-deficient mice with 300.19, a 
murine pre-B cell line expressing high levels of either human or murine BLTI allowed 
isolation of highly species specific anti-BLTI antibodies. Using an approach involving a 
series of human/murine BLTI chimeric receptors the monoclonal antibody binding sites 
were mapped to extracellular 100p-2. Extensive characterization of BLTI in murine 
v 
pnmary cells revealed high levels of BL Tl in neutrophils and eosinophils and a 
previously unsuspected regulation of BL Tl in macrophages. While bone marrow derived 
macrophages expressed high levels of BLTI its expression in peripheral tissue 
macrophages was significantly reduced suggesting a potential novel mechanism, and a 
role for BL Tl in inflammation-induced egress of bone marrow derived cells. The 
antibodies also allowed demonstration of normal BLTI expression in the recently 
generated BL T2 deficient mice. Future studies could explore the therapeutic potential of 
these antibodies. 
In Chapter III, we investigated the role of BLTl and BLT2 in inflammatory 
arthritis in mouse models. Collagen induced arthritis (CIA) is a model where mice are 
immunized with chicken collagen type II in complete freund's adjuvant and leads to a 
polyarthritis in the distal joints. BLTl deficient mice on the DBA!l background were 
completely protected from the development of CIA which confirms the prevIOUS 
observations with BLTI antagonists and BLTl deficient mIce on the C57B1I6 
background. 
Arthritis was also induced by transfer ofKlBxN serum to naIve mice. KlBxN is a 
T cell receptor transgenic mouse (KRN) crossed with a NOD mouse. These mice 
spontaneously develop arthritis due to auto-antibody production against glucose-6-
phosphate isomerase, a ubiquitous enzyme. In this model, we report for the first time that 
BL T2 deficient mice are completely protected from inflammatory arthritis. 
Histopathologic examination revealed a massive inflammatory cell influx in wild-type 
mice that was completely absent in BL T2 deficient mice. Further analysis of these mice 
using bone marrow transplantation studies demonstrated development of arthritis requires 
VI 
BL T2 expression on bone marrow-derived cells. Wild-type mice which received bone 
marrow from BLT2 -1- mice showed little sign of disease on histological analysis, while 
BLT2-1- mice receiving wild-type bone marrow showed intense inflammation leading to 
severe destruction in cartilage and bone. When BLTI/BLT2 double deficient mice were 
transplanted with a mixture of BL Tl deficient and BLT2 deficient bone marrow, a gain 
of clinical disease was observed. All these data demonstrate that BL T2 has a critical role 
in arthritis and it is non-redundant with the role played by BLTI. Further study is needed 
to determine the function of BL T2 and in which cell types it is important. 
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CHAPTER I 
GENERAL INTRODUCTION 
INTRODUCTION 
A. Biosynthesis of Leukotrienes 
Leukotrienes have been linked to inflammation for decades. The importance of 
these mediators was realized in 1980 when the slow-reacting substance of anaphylaxis 
was discovered to consist predominantly of L TC4 with a lower content of L TD4 and L TE4 
(1). In the same year, it was established that L TB4 serves as a potent chemoattractant for 
neutrophils (2). L TB4 is a derivative of arachidonic acid (AA), found in cell membranes. 
Upon activation of a cell, cytosolic phospholipase A2 releases AA from the membrane 
where it is acted upon by 5-lipoxygenase (5-LO) in concert with 5-lipoxygenase 
activating protein (FLAP) to produce leukotriene A4 (L T A4). L T A4 can either be 
converted to leukotriene C4 through the addition of glutathione (aSH) by LTC4 synthase, 
or alternatively, can be converted to LTB4 by LTA4 hydrolase (LTA4H). A scheme of 
leukotriene biosynthesis is shown in Figure 1. L T ~ is exclusively made by leukocytes 
and is exported to endothelial cells to be converted into L TB4 or L TC4 where L T A4 
hydrolase and L TC4 synthase are present, which is an interesting phenomenon termed 
transcellular synthesis(3). 
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Figure 1: The Arachidonic Acid Pathway. Arachidonic acid is synthesized from 
phospholipids by phospholipase A2 (PLA2). The conversion of arachidonic acid to 
leukotriene A4 (LTA4) by the enzyme 5-lipoxygenase is the first commited step in 
leukotriene biosynthesis. LT A4 is an unstable molecule and is hydrolyzed by L T ~ 
hydrolase (LT A4H) to form Leukotriene B4 (L TB4). Alternatively, LTA4 can be 
converted to LTC4 through the addition of glutathione. LTD4 and LTE4 are the 
metabolites of L TC4. 
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B. Leukotriene Receptors: 
Though the role of leukotrienes in inflammatory diseases was known long ago, it 
took considerable time to clone the receptors for these important mediators. There are 
two known receptors for LTC4, (CysLTI and CysLT2), and for LTB4 (the high-affinity 
receptor, BLTI and the low-affinity receptor, BLT2). The human CysLTI receptor was 
cloned in 1999 (4) followed by the cloning of the human CysLT2 receptor in 2000 (5). 
Human BLTI was the first to be cloned in 1997 (3), followed quickly by the murine 
BL Tl in 1998 (6). During the analysis of the promoter region of BL Tl, Y okomizo et al. 
identified an open reading frame (ORF) upstream of the BLTI gene. This ORF was 
subsequently identified by this and three other groups as coding for a low-affinity 
receptor of L TB4 and termed BL T2 (7-10). The homology ofthese receptors is shown in 
Box 1 (11). BLT2 is the most conserved receptor in mice and human. The deduced amino 
acid sequences of the BL Ts are shown in Figure 2 and Figure 3 as a snake diagram 
depicting extracellular loops, transmembrane regions and intracellular loops. We 
identified the transmembrane regions ofhBLTI and hBLT2 by molecular dynamic model 
simulation methods (12). The transmembrane regions of murine BLTs are predicted from 
hBLTs. 
78.6% 92.7% 87.3% 73.4% 
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mBLT1 
Figure 2: Snake Diagram of Human and Murine BLTl. Snake diagram (2D) are 
shown for the human BLTI (top) and murine BLTI (bottom). The approximate lengths 
of both the membrane-spanning regions and the extracellular loops were determined 
using molecular dynamics simulations ofBLTl (Basu et al). Human BLTI was used as 
an amino acid template to make murine BLTI. The amino acids that remain the same 
remain labeled in white text with a black background, while the amino acids that are 
different are labeled in white text with a red background. 
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hBLT2 
mBLT2 
Figure 3: Snake Diagram of Human and Murine BLT2. Snake diagram (2D) shown 
of the human BLT2 (top) and murine BLT2 (bottom). The approximate lengths of both 
the membrane-spanning regions and the extracellular loops were determined using 
molecular dynamics simulations ofBLT2. Human BLT2 was used as an amino acid 
template to generate murine BL T2. The amino acids that remain the same remain labeled 
in white text with a black background, while the amino acids that are different are labeled 
in yellow text with a purple background. 
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C. Expression and Function of BL Tl and BL T2: 
Although BL T1 was long known to be a neutrophil chemoattractant receptor, 
recent studies identified BLT1 expression on macrophages (13), smooth muscle cells 
(14), endothelial cells (15) , activated T cells (16), mast cells (17), and dendritic cells 
(18), considerably expanding the potential role of L TB4. BL T2 has been shown to be 
expressed widely in humans, with the spleen and peripheral blood leukocytes showing 
the highest levels of expression (10), while the expression of BL T2 in the mouse has been 
difficult to ascertain with several laboratories reporting variable results. Iizuka et al. 
demonstrated expression of murine BL T2 as being highest in the small intestine and 
lower in the skin by Northern blot. Using in situ hybridization, they were also able to 
demonstrate the presence ofBLT2 in the skin. Upon performing RT-PCR based analysis, 
they also found BLT2 in the colon and spleen at low levels (19). Another laboratory 
confirmed the expression of BL T2 in the spleen, but was unable to detect any BL T2 
signal in the skin (20). Using RT-PCR, expression ofBLT2 was demonstrated in murine 
mast cells (17). In similar studies, our laboratory as well as another group investigating 
BL T2 expression were unable to detect BL T2 expression in any of the cell types or 
tissues tested (21, 22). The reasons for these differences are unclear and must be 
resolved. Results in this thesis show expression of BL T2 in cells derived from the bone 
marrow. 
The regulation patterns of BL T1 and BL T2 remain elusive. Recently, 
dexamethasone has been shown to regulate the expression of BL T1 in a number of cell 
types including human neutrophils, monocytes and T-cells (23, 24). Stankova et al. 
demonstrated that dexamethasone up-regulates BLTI in human neutrophils in a time and 
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concentration dependent manner (24). Dexamethasone and IL-I0 were shown to up-
regulate BLTI expression in human monocytes, while IFNy, TNFa and LPS down-
regulated BLTI (23). Data demonstrating up-regulation of BLTI on CD8+ T effector 
cells will be shown in Chapter II. Low levels of BL Tl were discovered in resident 
peritoneal macrophages in rats (25). However, macrophages elicited by proteosepeptone 
showed an increase in the level of BL Tl expression in rats. LPS was demonstrated to up-
regulate BLTI in human umbilical cord vascular endothelial cells, while TNFa up-
regulated BL T2 (15). BL Tl expression was also up-regulated in smooth muscle cells 
upon treatment with IL-l~ or LPS. When a plasmid over-expressing IKK~, an inhibitory 
molecule for NFxB, was used in this assay, the BLTI up-regulation was blocked, 
suggesting a requirement of the NF-xB pathway in BLTI regulation (14). Further 
research is required to determine how the L TB4 receptors are regulated using both in vivo 
and in vitro models. 
Part of the regulation of BLTI is due to desensitization by phosphorylation of the 
receptors and ~-arrestin dependent internalization. Conflicting results about the 
importance of phosphorylation in internalization of the receptors have been published 
(26, 27). L TB4-induced internalization of BL Tl was demonstrated to occur in RBL-2H3 
cells that express high endogenous levels of GPCR kinase 2 (GRK2), while 
internalization of BL T 1 did not occur in COS-7 cells or HEK -293 cells which do not 
over-express GRK2. BLTI internalization was blocked in RBL-2H3 cells when treated 
with a dominant negative of GRK2. Internalization could be induced in HEK-293 cells 
by co-expressing with wild-type GRK2. All this data demonstrated that phosphorylation 
of BLTl is absolutely required for internalization of the receptor. They went on to 
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demonstrate that BLTI did not interact with arrestin either by fluorescence microscopy or 
by coimmunoprecipitation. Finally, this group demonstrated that the C-tail of BLTI was 
required for both GRK2 phosphorylation and internalization(26). In contrast, lala et al. 
from our laboratory demonstrated that internalization of BLTI is phosphorylation 
independent and ~-arrestin dependent (27). BLTI mutants, which lack phosphorylation 
sites in the C-tail (14 Ser/Thr are mutated to Ala) internalize through ~-arrestin. This 
mutant showed higher ligand-induced intracellular calcium release indicating a role for 
receptor phosphorylation in desensitization process. Functional importance of the 
internalization of BLTI was demonstrated by Gaudreault et al (28). They showed that 
the internalization and activation of BLTI occur through Yes kinase, which was found to 
be crucial for L TB4 induced degranulation of neutrophils. 
Though BL Tl and BL T2 are GPCRs and bind the same ligand, some differences 
III G-protein specificity exist between these receptors. In addition, the usage of G-
Proteins varies in different cell types. The chemotaxis of CHO cells expressing either 
human BLTI or human BLT2 was normal towards LTB4. The chemotaxis was 
completely abolished in cells treated with Bordetella pertussis toxin (PTX), which blocks 
Gai/O- dependent signaling. LTB4-induced intracellular calcium release was only partially 
blocked when cells were treated with PTX, indicating that calcium response was 
mediated by both PTX-sensitive and PTX-insensitive G proteins in CHO cells (3, 10). In 
contrast, L TB4-induced intracellular calcium release in human neutrophils was largely 
sensitive to PTX treatment (29). The three intracellular loops of BLTI were shown to be 
important for the binding of GUj and G 16 proteins in cells over-expressing BL TI along 
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with either GUi or G 16 proteins in COS-7 cell lines. A short region in ICL3 was shown 
to be critical in for the recognition of GUi protein (30) 
In functional assays, BLT2 was shown to be about 100-fold less sensitive to LTB4 
than BL Tl. Of interest is the finding that human BL T2 also can bind and display 
intracellular calcium release to l5(S)-hydroxyeicosatetraenoic acid (15(S)-HETE), l2(S)-
hydroxyeicosatetraenoic acid (12(S)-HETE), and 12(S)-hydroperoxyeicosotetraenoic acid 
(12(S)-HPETE), while BLTI is very specific for LTB4 (10) demonstrating that though 
both are considered L TB4 receptors, there are possible other functions of BL T2. These 
two receptors may also be distinguished based on the pharmacological specificity of the 
antagonists. Most of the antagonists were developed based on inhibition of BLTI 
function and, thus, are specific for this receptor. While a few BL T2 antagonists are 
identified, dual inhibitors are not well characterized at this time. CPI05,696 and U75302 
are both specific for BLTl, while L Y255283 is specific for BLT2 (10, 31). 
L TB4 mediated signal transduction pathways via BL T 1 such as chemotaxis (3), 
degranulation (32), adhesion (33) and prolongation of the cell survival (34) were 
functions previously attributed to BLTI in neutrophils. Recent data has started to 
delineate new roles for BLTI in neutrophils and in other cell types. For example, smooth 
muscle cells have been shown to migrate and proliferate in response to L TB4 through 
BLTI (14). Our laboratory has shown the presence of mRNA and LTB4 mediated 
chemotaxis via BLTI in immortalized murine macrophages (35). 
The expression of both BLTI and BLT2 was reported recently in human and 
murine mast cells (17). This group showed the presence of mRNA for both receptors in 
murine bone marrow-mast cells (mBMMC) and in human mast cells (hMC). They also 
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demonstrated L TB4 induced chemotaxis of these cells. The chemotaxis was blocked by 
either BL Tl or BL T2 specific inhibitors. It is interesting to note that mBMMCs 
chemotaxed towards 12-(S)-hydroxyeicosotetraenoic acid, which is a BL T2-specific 
agonist. The data clearly suggested that both receptors are functional in mast cells. 
Another new cell type that the L TB4 receptors have been described in is endothelial cells. 
BL Tl and BL T2 were shown to be expressed in human umbilical vein endothelial cells 
(HUVEC) at low levels. Up-regulation ofBLTl (mRNA and protein levels) were seen in 
vitro when HUVEC cells were treated with LPS, while treatment with TNFa led to an 
increase in BLT2 mRNA (15). Expression on subsets of T cells has also been 
demonstrated. It was shown that activating naIve T cells in vitro with anti-CD3 caused 
up-regulation of BLTI in ThO, Thl and Th2 cells and these cells demonstrated 
chemotaxis toward L TB4, suggesting a functional role of BL Ts in activated T cells. This 
response was not seen in the mice lacking B L T 1 (16) highlighting the fact that L TB4 
mediated signaling occurs via BLT1. 
Recent experiments from our laboratory have demonstrated functional expression 
of BLT1 on both mature and immature dendritic cells (18). It was shown that exposure 
of immature dendritic cells (iDC) and mature dendritic cells (mDC) to LTB4 greatly 
enhanced chemotaxis to the CCR 7 ligands CCL 19 and CCL21 suggesting a priming 
effect for L TB4. In vivo, it was shown that mice in lacking both BL Tl and BLT2 
(BLT1I2 KO) mDCs had a deficiency in trafficking to the popliteal lymph nodes when 
compared to wild-type mDCs at 20 and 48 hours. In contact hypersensitivity (CHS) 
experiments, it was seen that BLT1I2 KO DCs very poorly initiated a CHS response 
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when compared to wild-type DCs. These data together show that BLTI has a direct 
effect in the control of adaptive immune responses. 
D. Role of L TB4 and its receptors in various inflammatory diseases: 
We now have a better understanding of expression patterns of BLTI and BLT2; 
however the role of L TB4 in disease processes is yet to be fully uncovered. L TB4 is up-
regulated in many human diseases and can be found in atherosclerotic plaques (36, 37), 
rheumatoid arthritis synovium (38), and in exhaled breath condensates in asthma patients 
(39). Further illustrating the importance of LTB4 in human disease, recent population 
studies have shown that certain L T A4H and FLAP polymorphisms in humans predispose 
individuals to increased risk of myocardial infarction and stroke (40, 41). This means 
that regulation of L TB4 biosynthesis is directly attributable to this increased risk. When 
samples from chronic obstructive pulmonary disease patients were analyzed, it was found 
that BLTI was very highly expressed and could be found in macrophages, CD8+ T cells 
and neutrophils potentially implicating all three cell types in the disease process (42). 
a) Atherosclerosis: 
Mouse models of human disease have proven useful in delineating the role of 
BL Tl in inflammatory diseases. Of these, models of atherosclerosis have demonstrated a 
direct role ofBLTI in disease progression. Mice deficient in 5-LO were shown to have a 
26-fold decrease in lesion development in an atherosclerosis model. In these studies, it 
was shown that macrophages in the plaques abundantly expressed 5-LO (43). 5-LO 
deficiency was also shown to protect mice from aortic aneurysm (44). Models utilizing a 
BLTt antagonist, CP-I05,696, in Ldl -1- and ApoE -1- mice showed a reduced 
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accumulation of CD 11 b+ cells in the lesions and limited lesion size (45). Our laboratory 
was the first to demonstrate that the loss of BLTI protects mice from the development of 
atherosclerotic disease. We found a significant decrease in plaque size in the early stages 
of disease. The plaque analysis of BLTI-/- mice revealed a reduction in macrophage 
accumulation compared to plaques of BLTI +/+ mice. It was also shown in the same 
study that L TB4 up-regulated monocyte chemotactic protein-I, CD36, urokinase-type 
plasminogen activator, colony stimulating factor-I, and osteopontin (35), all of which 
already have an established roles in atherogenesis. Up-regulation of MCP-l by L TB4 was 
confirmed in human monocytes (46). This demonstrates that the LTB4-BLTI axis 
provides an amplification loop to attract monocytes and macrophages to the site of plaque 
formation and also leads to the destabilization of the plaque. Another cell type important 
in the disease is the smooth muscle cells. The expression of BL Tl on smooth muscle 
cells as stated before was shown and allowed for the chemotaxis of smooth muscle cells 
towards LTB4. This paper demonstrated loss of BLTI led to a decrease in the thickness 
of smooth muscle cells in the plaque as well as T cells and macrophages (14). In addition 
to being a key molecule in plaque progression, recent data have demonstrated that 
symptomatic plaques express high levels of L TB4 which correlates with plaque 
destabilization (47) a phenomenon that was confirmed when it was found that expression 
of 5-LO and L T A4H in plaques led to their destabilization (48). Population studies 
recently have shown that polymorphisms in LTA4H and FLAP predispose the individual 
to increased risk of myocardial infarct (40, 41). 
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b) Asthma: 
A vast amount of research involving L TB4 in asthma has been performed owing 
to the fact that high levels of LTB4 are present in the airways of asthmatic patients (39). 
In 2003, the discovery that CD8+ effector T cells express BLTI was made (49). It was 
found that CD8+ effector T cells were able to chemotax towards L TB4, while naIve or 
central memory T cells were unable. It was also shown that CD4+ Thl and Th2, but not 
ThO T cells expressed BLTI as they left the lymphoid compartment and entered into 
tissue (16). It was found in collaboration with our laboratory, that BLTI-/- mice have 
decreased airway hyper-responsiveness in an ovalbumin-induced airway hyper-
responsiveness (AHR) model (50). Reconstitution of allergen sensitized BLTI +/+ T 
cells fully restored AHR in BLTI-/- mice suggesting a role of BLTI in AHR. A 
reduction in goblet cell hyperplasia and interleukin-13 was also seen in BLTI-/- mice in 
that study. This group performed another model of AHR which is mast cell-dependent. 
In these studies, mice were sensitized with anti-ovalbumin (OVA) IgE and then 
challenged with OV A in the airways. This model requires mast cells for the sensitization 
from IgE and CD8+ cells for the reactive phase of the model. Wild-type mice develop 
altered airway function, while CD8 -/- mice do not. CD8 -/- mice reconstituted with 
CD8+ T cells develop AHR, while CD8 -/- mice reconstituted with BLTI-/- CD8+ T 
cells do not develop AHR (51). This result was confirmed by another laboratory who 
saw loss of AHR in another strain of mice deficient in BLTI (52). It was found that only 
small populations of T cells express BLTI in healthy individuals. The population 
increases with Epstein - Barr virus infection and in asymptomatic allergy. The increase 
in BLTI expressing T cells was seen only in the airway and not in the blood (53). A 
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similar result was seen in asthmatic patients where BLTI expressing CD8+ T cells were 
found in broncheo-alveolar lavage and in lung tissue, while no BLTI expressing CD8+ T 
cells were found in healthy volunteers (54). These results suggest that BLTI might be a 
useful target in asthma. 
c) Other Inflammatory Diseases: 
L TB4 has also been implicated in many other inflammatory diseases such as 
inflammatory arthritis, a major focus of studies in this thesis (Chapter III). In addition, 
L TB4 was also shown to be important in experimental autoimmune encephalomyelitis 
(EAE) and peritonitis. It was found that the eosinophil recruitment in EAE is dependent 
on L TB4 receptor ligation and further revealed a previously unrecognized role for 
eosinophils in the pathogenesis of this disease (55). In a mouse model of peritonitis, 
LTB4 and BLTI were found to play important roles in the recruitment and/or retention of 
leukocytes, particularly eosinophils (56). Using BLTI deficient mice developed in our 
laboratory, Liao et al. demonstrated an important role for LTB4 and BL Tl in auto-
immune uveitis (57). Adoptive transfer experiments showed that expression of BL Tl is 
important on both auto-reactive T cells as well as on innate immune effector cells 
The major focus of our laboratory for the last 10 years has been to develop a 
complete understanding of the structure/function, regulation and biological activities of 
the L TB4 receptors. These studies used cell and molecular biological approaches as well 
as mice deficient in the LTB4 receptors BLTI and BLT2 (12, 21, 27, 35, 58-60). The 
work described in this thesis attempts to further our knowledge of the biology of L TB4 
receptors by developing highly specific monoclonal antibodies for BLTI (Chapter II) and 
demonstrating the functionalsignificance ofBLT2 (Chapter III). 
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CHAPTER II 
GENERATION AND CHARACTERIZATION OF 
MONOCLONAL ANTIBODIES AGAINST HUMAN AND 
MURINEBLTI 
INTRODUCTION 
Evolving technologies have allowed our laboratory and others to demonstrate the 
presence of BLTI on cell types that had not previously been known to express BLTI in 
the last few years (13-18). We have developed monoclonal antibodies to BLTl, which 
allowed us to probe for the expression of BLTI and if any regulation patterns exist. 
Chapter II will focus on the generation and characterization of these newly described 
monoclonal antibodies. 
The term monoclonal antibody simply means an antibody that has a defined 
specificity because it arose from one original plasma cell. To produce a monoclonal 
antibody, a vertebrate animal is immunized with the molecule of interest either purified, 
conjugated to a carrier protein such as keyhole limpet hemocyanin (KLH), or on cells 
expressing the molecule. Multiple rounds of immunization lead to the selection and 
expansion of B cells that recognize the molecule in the spleen or lymph nodes. These 
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tissues can be taken and the cells extracted and fused with a myeloma cell line using 
polyethylene glycol (PEG). When grown in culture, the unfused plasma cells have a 
limited life-time and die. The myeloma cells used are unique in that they lack the 
hypoxanthine-guanine-phosphoribosyltransferase (HGPRT) gene, which allows them to 
make purines using hypoxanthine. In medium containing hypoxanthine, aminopterin and 
thymidine (HAT), unfused myeloma cells do not survive due to the loss of the HGPRT 
gene. A hybridoma fusion between a plasma cell and a myeloma cell will be immortal 
and will contain a functional HGPRT gene, therefore, only these fused cells will survive. 
These cells are diluted so that only one fusion will give rise to a population of cells 
which make a monoclonal antibody. The resultant monoclonal antibodies are then 
screened against the antigen by enzyme-linked immunosorbent assays (ELISA) or 
similar methods or, as in this assay, if the antigen is on a cell surface, flow cytometry can 
be used. 
Monoclonal antibodies are valuable and unique tools to detect and block the 
antigen functions in biological systems. In research, monoclonal antibodies are used for 
Western blotting, immunofluorescence, immunohistochemistry , FACS, 
immunoprecipitation, affinity chromatography and ELISA. Many ELISA kits are 
available utilizing monoclonal antibodies such as for drug screening and pregnancy tests. 
Monoclonal antibodies also have gained acceptance as treatments in human disease such 
as cancer and rheumatoid arthritis and in organ transplantation. In the treatment of 
cancer, there are two main types of monoclonal antibodies in use. The first are the naked 
antibodies, which are not conjugated to another molecule. Some naked antibodies such 
as Rituxan (61) and Campath (62) bind to the surface target and induce the host immune 
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system to destroy the tumor. Other naked antibodies such as Herceptin (63), Erbitux (64) 
and A vast in (65) are used to block surface proteins that are necessary for tumor cell 
survival or growth. The other group of antibodies is the conjugated antibodies which are 
attached to drugs, toxins or radioactive substances. Only the radiolabeled antibodies 
Zevalin (66) and Bexxar (67) are currently approved for use in the clinic at this time; the 
others are still in clinical trials. OKT3, an antibody against the T3 antigen on T cells, is 
used to combat organ rejection in patients who have received an organ transplant (68). 
Remicade (69), Humira (70), and Rituxan (71) are currently being used to treat 
rheumatoid arthritis. Remicade and Humira are both antibodies against TNFa and have 
been effective in combination with methotrexate in halting the progression of RA. 
Rituxan targets B cells and has also shown promise in treating RA. 
Given all the disease processes mediated by L TB4 and its receptors, monoclonal 
antibodies against BL Tl might prove to be useful in treatment of inflammatory diseases. 
Although monoclonal antibodies have been available for human BL Tl for several years 
(72, 73), anti-BLTI antibodies that recognize BL Tl in small animals would be useful to 
allow studies in mouse models of disease. Due to the potential usefulness of monoclonal 
antibodies that recognize a common epitope between hBLTI and mBLTl, we initiated 
experiments to produce these antibodies utilizing our BL T 1-/- mice. The technique that 
was used had been performed successfully to produce L-selectin antibodies (74) which 
involves the use of 300.19 mouse pre-B cells. The parental 300.19 cells were transfected 
with HA-tagged hBLTI with an expectation that since hBLTI and mBLTI are highly 
homologous, we would get antibodies that were cross-reactive for both. Unfortunately, 
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immunization with 300.19 cells expressing HA-tagged hBLTI resulted in the isolation of 
over 15 antibodies, all of which turned out to be specific for the HA-tag. 
A new strategy was adopted, where red fluorescence protein (RFP) was fused at 
the c-terminal end of BLTI without HA-tag. The hBLTI-RFP localized to membrane 
suggesting fused RFP did not alter the folding of BLTI. The expression of hBLTI-RFP 
was measured by the fluorescence of RFP. The cells expressing stable hBLTI-RFP 
clonal lines were selected and experiments were repeated as described above. This 
resulted in the production of over 30 monoclonal antibodies which all turned out to be 
specific for hBLTI and showing no reactivity against mBLTI. Therefore, mBLTI fused 
to tetramer RFP was expressed and put through the same protocol and this led to the 
production of 8 mBLTI antibodies. These antibodies have allowed us to demonstrate the 
expression of BLTI on human neutrophils and have allowed us to determine the 
expression pattern of BLTI in different mouse tissues. Out of these results came new 
data demonstrating differential expression of BLTI on macrophages depending on their 
activation status and tissue localization. 
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MATERIALS AND METHODS 
Materials 
CD3-FITC, B220-PE, NK1.I-PE, GR-I-PE, Siglec-F-PE, CD45.I-PE, CD45.2-
FITC, CD 11 b-FITC, CD 16-PE and Streptavidin-conjugated APC were all from BD 
Pharmingen. GR-I-FITC was from Ebiosciences. 
Generation of 300.19 Cells Expressing Murine and Human BL Tl 
300.19 cells were maintained as a suspension culture in RPMI-1640 medium 
containing 2 mM L-glutamine, 10% FBS, I X ~-mercaptoethanol, and 1% 
penicillin/streptomycin. Transfections were done by electroporation. 20 ~g of pDSRED-
NI encoding human BLTI or mouse BLTI was electroporated into the cells and cells 
were sorted by flow cytometric sorting. Single cell clones were made by limiting dilution 
and the expression of functional receptor was tested by calcium flux in response to L TB4. 
Immunization Protocol for 300.19 cells Expressing BL Tl 
300.19 cells expressing hBL TI or mBL TI were harvested at 1500 rpm for 3 
minutes and the cell pellet washed three times with PBS. 50 million cells were 
resuspended in I mL of PBS and injected s.c. on the back ofBLTI-I- mice on the Balb/c 
background. Within a week a large tumor grew at the site of injection and this tumor 
resolved by two weeks. On day 14, another injection of 50 million cells was given i.p. as 
a booster and again on day 21. On day 23, a sample of blood was taken and the plasma 
isolated. The plasma was used to stain 300.19 parental cells and 300.19 cells expressing 
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BLTI to check for specific staining for BLTI over background staining of the parental 
cells. On day 24, the mice were sacrificed for hybridoma production. 
Hybridoma Production 
Mice were sacrificed and their spleens were removed. The spleens were placed in 
a culture dish with 10 mL cDMEM-O (1% Nonessential Amino Acids, 2 mM L-
glutamine, 50 /-lM 2-mercaptoethanol, 5000 units penistrep) and wire mesh size 60 
(Sigma-Aldrich). The spleens were teased with two 21 gauge needles. The debris was 
removed by pipetting through the mesh filter several times. The medium was transferred 
into 50 mL Falcon tubes and the volume was increased to 45 mL with cDMEM. 0.3 mL 
of FBS was layered under the medium to allow any clumps to settle out for about 3 
minutes. The medium was carefully pipetted off from the FBS and placed in a new clean 
50 mL tube and spun at 1500 rpm for 5 minutes. The supernatant was discarded and 45 
mL of cDMEM-O was added to resuspend the cells. SP2/0 myeloma cells were taken and 
placed in several 50 mL tubes and both SP2 and spleen cells were spun at 1500 rpm for 5 
minutes. The supernatants were discarded and the spleen cells and SP2/0 were washed 
twice. The SP2/0 and spleen cells were resuspended separately in 10 mL cDMEM-O and 
enumerated. The SP2/0 and spleen cells were mixed at a 1: 1 ratio in a 50 mL tube and 
the tube was filled with cDMEM-O and then spun at 1500 rpm for 5 minutes. The 
supernatant was aspirated off and 1 mL of 50% polyethylene glycol (PEG) was added 
slowly to the pellet over 1 minute drop-wise stirring after each drop. Then, another 1 mL 
of prewarmed cDMEM was added to the pellet over 1 minute drop-wise stirring after 
each drop. The addition of medium was repeated once more, and then 7 mL of cDMEM 
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was added drop-wise over 2-3 minutes. The cells were spun at 1500 rpm for 5 minutes. 
The supernatant was discarded and the pellet was resuspended in the volume of cDMEM-
20/HEPES (10mM HEPES) to give a concentration of 2.5 X 106 cells/mL. 100 ilL of 
medium was added to each well of a 96-well plate. On day 2 of the experiment, 100 ilL 
ofDMEM-20/HEPES/HAT (1 X HAT) was added to each well. On days 3,4,5, 7, 9 and 
11, half the volume in the well was removed and another 100 ilL of DMEM-
20/HEPES/HAT was added to each well. On day 14, half the medium was removed from 
each well and 100 ilL of DMEM-20/HEPES/HT was added. Starting on day 15, any 
media changes were done with DMEM-20/HEPES. 
Screening of Hybridomas 
Hybridomas were allowed to grow until they reached approximately 50% 
confluence. A sample of 10 ilL from the supernatant was removed and incubated with a 
mixture of 5 X 105 parental 300.19 cells and 5 X 105 300.19 cells expressing HA-tagged 
hBLTI in 500 ilL of PBS + 1 % BSA and incubated for 1 h at 4°C. The cells were 
washed with PBS + 0.1 % BSA and resuspended in 200 ilL of PBS + 1 % BSA containing 
1 ilL of goat anti-mouse IgG (Jackson Immunoresearch) and incubated for 45 m at 4°C. 
The cells were washed once with PBS + 0.1 % BSA, resuspended in buffer and analyzed 
by flow cytometry. Cells were acquired on FACSCalibur (BD Biosciences) and 
subsequent analysis was done with FlowJo version 4.3 (Treestar, Inc.). 
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Monoclonal Antibody Purification and Biotinylation 
Hybridomas were grown in RPMI-1640 medium containing 2% or less of FBS 
and grown to a high concentration for high level production of antibody. 500 mL of this 
medium was resuspended in 50% ammonium sulphate to precipitate the antibody. The 
antibody was resuspended in 1 X PBS and dialyzed to remove the ammonium sulphate 
and HPLC was performed on a Mono Q HR column (GE Healthcare). Peak protein 
fractions were taken and used to stain BL Tl expressing cells to check antibody activity. 
Those fractions that had the highest amount of activity were taken and biotinylated using 
the EZ-link sulfo-NHS-LC-biotin kit (Pierce). 
Random Chimeragenesis 
Random chimeras between human and mouse BLTI were generated following a 
protocol used previously to make chimeras of cAMP receptors (75). The plasmid 
pCDNA3.l+hmBl was used to produce the hBLTl and mBLTl chimeras. The sequence 
for hemagglutinin-tagged hBLTl was cloned between the Nhe I and Hind III sites of 
pCDNA3.l+. The sequence for mBLTl was then cloned between the EcoR I and Not I 
sites of the plasmid containing hBL Tl. After the chimeragenesis procedure, the chimeric 
receptor was flanked by Nhe I on the 5' end and Not I on the 3' end. The pcDNA3.l+ 
vector was linearized by double digestion with EcoR I and Hind III restriction enzymes, 
which were located between both the genes. After testing by gel electrophoresis whether 
digestion was complete, the enzymes were inactivated at 65°C for 30 minutes. The 
digested DNA was gel-purified. The digested DNA (750 ng) was used to transform E. 
coli strains DH5a and TOPlO (Invitrogen) competent cells by heat shock and plated on 
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LB plates containing ampicillin. 16 colonies were taken from the DH5a plate and 16 
colonies from the TOPlO plate and analyzed by restriction analysis to check for a 1 kb 
insert. 28 of these clones were determined to contain the correct size insert and were 
digested separately with 3 restriction endonucleases; Xho I which is found at 243 bases in 
mBLTl, Kpn I which is found at 517 bases in hBLTl, and EcoN I which is found at 728 
bases in hBL Tl. This analysis allowed us to break down the clones into 4 quadrants 1-4 
where crossover occurred. 9 clones were located in quadrant 1, 6 in quadrant 2, 11 in 
quadrant 3, and 6 in quadrant 4. The clones were confirmed by sequencing using primers 
on either side of the multiple cloning site of the vector. 3 to 4 clones were sequenced 
from each quadrant leading to the identification of 9 unique sites of crossover. 
Staining of Human Neutrophils 
Human volunteer blood was collected by venapuncture in 60 mL synnges 
containing 5 mL of 3.8% w/v sodium citrate anticoagulant. An equal volume of 3% 
Dextran T-500 in PBS was mixed and red blood cells were allowed to sediment for 30 
minutes at room temperature. The leukocyte-rich plasma was aspirated above the red 
cells with a syringe with tubing attached. The plasma was distributed in 15 mL volumes 
into 50-mL disposable tubes and then under-laid with 10 mL of 1.077 g/mL density 
Ficoll-Hypaque solution using a 20 mL syringe with tubing on the end. A layer of 1.105 
g/mL Ficoll-Hypaque was then placed under the 1.077g/mL Ficolliayer. The tubes were 
centrifuged for 30 minutes at 1000 g. Each tube contained a red cell pellet and two white 
interface layers. The lower interface was taken which contained> 98% neutrophils. The 
neutrophils were pooled into one tube to about 20 mL and 30 mL of PBS was added. The 
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tubes were mixed and centrifuged at 1200 rpm for 12 minutes. The supernatant was 
decanted and the tube was blotted on a paper towel leaving the white cell pellet. The 
pellet was washed twice with PBS and centrifuged at 1000 rpm for 10 minutes. The cells 
were resuspended in PBS and were counted. 500,000 cells were placed in several F ACS 
tubes and the cells were washed with PBS + 0.1 % BSA. The cells were then resuspended 
in 0.5 mL of PBS + 1 % BSA. 1 0 ~L of several culture supernatants from positive 
hybridomas was added to separate tubes. The remaining procedures were done as above. 
Murine Antibody Screening of Primary Cells and Cultured CD8+ T cells 
Flow cytometry was performed using four samples from mice; blood, bone 
marrow, spleen and lymph nodes. Mice were euthanized and the skin on the abdomen 
and thoracic area were opened up to enable blood collection by cardiac puncture into 
tubes containing heparin (MP Biomedicals). The entire ventral surface from under the 
jaw of the mouse down to the base of the hind-limbs had the skin laid open to reveal the 
lymph nodes. The superficial cervical, axillary, brachial and inguinal lymph nodes and 
spleen were removed and the leukocytes were isolated. Bone marrow was isolated from 
the femurs and tibias and leukocytes were isolated. These samples were resuspended in 
1 00 ~L of PBS + 1 % BSA containing 1 ~L of biotinylated 3D7 and a number of 
conjugated cell surface markers. The tubes were then incubated for Ih at 4°C and washed 
with PBS + 0.1 % BSA. The cells were resuspended in 200 ~L on PBS + 1 % BSA 
containing 1 ~l of streptavidin-conjugated APC and incubated for 45m at 4 T. 2 mL of 
BD F ACS Lysing Solution was added to blood samples and 1 mL added to the remaining 
samples and incubated at room temperature for 1 h. The cells were washed, resuspended 
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and analyzed by flow cytometry. This same procedure was used to stain CD8+ effector 
and central memory T cells. 
Dexamethasone Up-regulation of BLTI in CD8+ T cells 
Mononuclear cells collected from lymph nodes and spleen of OT -1 TCR 
transgenic mice were stimulated with 1 /lg/mL of SIINFEKL peptide for 90 min. After 
washing, cells were cultured for 2 days in complete media (RPMI-1640 medium 
supplemented with 10% heat-inactivated FCS, 50 /lM 2-ME, 100 U/mL penicillin G, 100 
/lg/mL streptomycin, and 10 mM HEPES). Cells were then washed and cultured in 
complete media containing 20 ng/mL of either recombinant murine IL-12 for generation 
ofTEFF cells or IL-15 for TeM cells. To address the effect of DE X on memory CD8+ T 
cells, dexamethasone 21-phosphate disodium salt (DEX; Sigma-Aldrich) was added to 
the culture medium during differentiation of these cells. Medium containing cytokine 
and/or DEX were changed everyday. After 5 days, cultures were shown to contain> 
99% a~/CD8+ T cells. CD4+, CDllc+, NK1.1+ or y8+ cells were <0.1%. The cells 
were >90% either CD8+ effector memory or central memory cell phenotype, as shown by 
the CD62L1CCR 7 cell surface marker. T EFF cells derived through this protocol showed 
phenotypic and functional characteristics of effector memory CD8+ T cells in vivo. Cells 
were used between days 5 and 8 of culture after addition of either IL-2 or IL-15. 
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RESULTS 
Generation of hBL Tl and mBL Tl Specific Monoclonal Antibodies 
300.19, a murine pre-B cell line expressing high levels of human BLTI was used 
to immunize BL Tl deficient mice in BALB/c background as described in methods. Two 
days before sacrifice, a blood sample was taken and the plasma was analyzed for 
reactivity to hBLTI. This analysis is shown in Figure 4, where the red line represents 
parental 300.19 cells and the blue line represents 300.19 cells expressing hBLTl. As 
expected, the plasma from immunized mice showed reactivity against 300.19 cells. 
However, 300.19 cells expressing hBL Tl showed a considerable increase in mean 
fluorescence demonstrating specific activity against hBLTI. 
Based on this observation, spleens were removed from these mice and fused with 
SP2/0 myeloma cells to form hybridomas as described in methods. The cells were 
diluted at a ratio (2.S X 105/mL) so that positive wells should arise from only one 
hybridoma, thereby making it monoclonal. As the cell growth in a 96-well plate reached 
approximately SO% confluence the supernatants were taken and analyzed by flow 
cytometry. A simple screening method using equal amounts of parental 300.19 cells and 
300.19 cells expressing HA-tagged hBLTI was used for rapid detection of positive 
clones (Figure S). By this method, we anticipated no reactivity when the supernatants 
contained no antibody (negative, Figure Sa) whereas a complete shift indicated a 300.19 
cell specific antibody (Figure Sc) and half the cells reacting indicated the presence of a 
potential BLT1 specific antibody (Figure Sb). Results representative of all three 
scenarios are shown in Figure 5 for hBLTl. 
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Figure 4: Plasma Screening of hBLTl Immunized Mice. BLT1 -1- Balb/c mice were 
immunized with 300.19 cells expressing hBLTl and boosted twice with the same cells. 
Plasma was isolated from one of these mice and was used to stain 300.19 parental cells 
(red line) and 300.19 cells expressing hBLTl (blue line). 
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Figure 5: Screening Strategy for Detecting Hybridoma Supernatants with hBLT1-
Specific Antibodies. The supernatant of hybridoma culture (10 JlL) was added to an 
equal mixture of 300.l9 parental cells and 300.19 cells expressing HA-tagged hBLTl. 
Goat anti-mouse IgG-FITC was used as secondary antibody. The 300.19 cells were 
analyzed on the FLI gate for FITC staining. Three representative results are shown. a) 
Culture supernant with no detectable antibody b) Culture supernatant containing an 
antibody that recognized 300.19 cells. c) Parental 300.19 antibody. 
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Cells from individual wells that showed hBL T1 specific staining (pattern as seen 
in 5b) were further expanded and antibody specificity of the supernatants to hBL T 1 was 
confirmed by staining parental 300.19 and 300.19 cells expressing hBL T1 separately. 
Many of these were further analyzed for reactivity against other cell lines expressing 
human or murine BL T 1 as well as human and murine neutrophils. The results of these 
analyses are shown in Table 1 where the level of binding was rated as - for no binding or 
+ to +++++ for how well they stained cells expressing the indicated forms of BLT1. As 
seen in Table 1, these monoclonal antibodies stained hBL T1 fused to RFP in 300.19 cells 
and HA-tagged hBLT1 in rat basophilic leukemia (RBL) cells. There was, however, no 
staining when the monoclonal antibodies were tested against 300.19 cells expressing HA-
tagged mBLT1. In addition, zymosan-elicited murine neutrophils which are known to 
express BL T1 at high levels also showed no detectable staining. 
Since monoclonal antibodies to mBLT1 would be a very useful tool to investigate 
the role of BLT1 in mice, the same technique as above was used with 300.19 cells 
expressing mBLT1. The resulting antibodies from this experiment are shown in Table 2. 
All these antibodies were found to be specific for mBLT1 showing no staining for cells 
expressing hBLT1. 
29 
300.19 RBL 300.19 Murine Human 300.19 
Clone 10 hBLT1-RFP hBLT1 mBLT1 Neutrophil Neutrophil hBLT1-DG 
2A8 ++++ +++ 
- -
++ ++++ 
2A8-SC2 N.D. +++ N.D. N.D. N.D. ++++ 
5B10 +++ + N.D. N.D. N.D. +++ 
6H12 ++++ +++ 
- -
++ ++++ 
7A5 + + + N.D. N.D. ++ 
7G6 +++ ++ 
-
N.D. N.D. +++ 
7G6-SC2 ++++ ++ 
- N.D. N.D. +++ 
8E8 ++++ + 
-
N.D. N.D. +++ 
8H7 +++ ++ 
-
N.D. N.D. +++ 
9A4 +++ ++ 
-
N.D. N.D. ++++ 
9B10 +++ + 
- N.D. N.D. + 
9E12 +++ ++ 
- - N.D. ++++ 
9G8 ++++ ++ 
- - N.D. ++++ 
10C8 +++ ++ 
-
N.D. N.D. +++ 
10C8-SC3 +++++ ++++ 
-
N.D. N.D. +++++ 
1101 ++++ +++ 
-
N.D. + +++++ 
11G3 + + 
-
N.D. N.D. ++ 
12B1 + + N.D. N.D. N.D. +++ 
12F1 ++ + 
- - -
++++ 
13C3 +++ + 
-
N.D. N.D. +++ 
13C3-SC1 ++++ +++ 
-
N.D. N.D. +++++ 
13E2 +++ + 
- -
N.D. ++ 
13E2-SC8 ++++ +++ 
-
N.D. N.D. +++ 
13F2 ++++ +++ 
- -
++ +++++ 
13F8 + + 
-
N.D. N.D. ++ 
14A7 ++ ++ 
-
N.D. N.D. ++++ 
1409 +++ + 
- - -
+++++ 
14E8 + + 
-
N.D. N.D. ++++ 
14E8-SC6 +++ ++ 
-
N.D. N.D. ++++ 
14F11 +++ + 
-
N.D. 
-
+++++ 
15A3 +++ N.D. 
-
N.D. N.D. N.D. 
15E6 ++ N.D. 
-
N.D. + N.D. 
16A12 ++++ N.D. 
-
N.D. N.D. N.D. 
1608 ++++ N.D. 
-
N.D. N.D. N.D. 
16A10 ++ N.D. 
-
N.D. N.D. N.D. 
1602 ++ N.D. ++ N.D. N.D. N.D. 
17E6 N.D. N.D. N.D. N.D. N.D. N.D. 
17G4 N.D. N.D. 
-
N.D. N.D. N.D. 
16F1 N.D. N.D. 
-
N.D. N.D. N.D. 
17F9 ++++ N.D. 
-
N.D. N.D. N.D. 
6F4 + N.D. N.D. N.D. N.D. N.D. 
3G9 + N.D. 
-
N.D. N.D. N.D. 
Table 1: Human BLTI Monoclonal Antibody Species Specificity. A panel of hBLTl 
monoclonal antibodies were used to stain hBLTl fused to different tags and expressed in 
various cell types or primary cells. For each cell type, each antibody is ranked as N.D. 
for not determined, - for negative, + for mean fluorescence (MF) of 20-1 00, ++ for MF of 
101-250, +++ for MF of251-500, ++++ for MF of501-1000 and +++++ for MF of 1001 
or more. 
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300.19 mBLT1 300.19 hBL T1 
2E4 + -
3A5 ++ -
307 +++++ -
4A12 ++ -
5E6 + -
6B1 +++ -
6E2 +++++ -
6F11 +++++ -
Table 2: Reactivity of Murine BL Tl Monoclonal Antibody. A panel of 
mBLTl monoclonal antibodies was used to stain cells expressing mBLTl or 
hBLTl tagged with RFP. For each cell type, the antibody is ranked as N.D. for 
not determined, - for negative, + for mean fluorescence (MF) of 20-100, ++ for 
MF of 101-250, +++ for MF of 251-500, ++++ for MF of 501-1000 and +++++ 
for MF of 1001 or more. 
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Analysis of parental 300.19 cells (solid line), 300.19 cells expressing hBLT1 
(dotted line) and 300.19 cells expressing mBLT1 (dashed line) stained separately with 3 
different antibodies is shown Figure 6. These three cell lines were stained with 12CA5, 
an antibody that recognizes the HA epitope tagged to hBLT1 and mBLT1 (Figure 6a). 
As seen in Figure 6a, the parental 300.19 cells did not stain with 12CA5, whereas cells 
expressing the HA-tagged versions ofhBLTI and mBLT1 stained positive for 12CA5. In 
Figure 6b, 6H 12 (a hBL T 1 specific mAb) was used to stain the cell lines and only stains 
300.19 cells expressing hBLTl. In contrast the 6B1 (a mBLT1 specific mAb) reacted 
with only 300.19 cells expressing mBL T1. These data are representative of all the mAbs 
tested against hBLTI and mBLTI and demonstrate that the antibodies produced are 
species specific for the type of BL T 1 used to immunize the mice. 
Epitope Mapping of hBL Tl Monoclonal Antibodies 
We next wanted to determine epitope specificity of anti-BLT1 antibodies. To 
accomplish this, a series of chimeras between hBLT1 and mBLT1 were made using 
random chimeragenesis. This method takes advantage of the ability of E. coli to carry 
out homologous recombination between related sequences in vivo. The hBL T1 and 
mBLT1 proteins are highly homologous with ~ 75% identity. A flow diagram for the 
strategy is shown in Figure 7 and the methodology described in the Methods section. 
Utilizing unique restriction enzyme sites in either gene, we were able to divide the 
resulting chimeras into quadrants where crossover occurred. Based on this information, 
several chimeras were sequenced to determine the exact region of crossover and 
representative chimeras are shown in Figure 8, where the hBL TI region is shown in pink 
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and the mBL Tl region is shown in blue. The designation below each chimera denotes 
where the protein sequence ends for hBL Tl and begins for mBLTl. Four chimeras 
(BlC7, BlC29, BlC22, and BlC8) were transiently transfected into HEK-293 cells and 
used to test binding of the human mAbs by flow cytometry. The data shows that all 
chimeras reacted with l2CA5 antibody at similar levels (Figure 9a and 9c) indicating 
normal surface expression of each chimera. In contrast, only hBL Tl, B 1 C7 and B 1 C29 
reacted with 6H12, the human BLTI mAb, but not with mBLTl, BlC22 or BlC8 (Figure 
9b, 9d and ge). Since the antibody can only react with extracellular surface domains, 
these results suggest that the extracellular loop 2 (ECL2) is likely the binding site for the 
monoclonal antibodies. As this region is replaced with the corresponding region from 
murine BLTl, loss of binding occurs. Quantification of the data with other hBLTl mAbs 
shown in Figure 6e confirms the finding with 6H12 and suggests that all hBLTl 
antibodies are likely to react with the similar epitopes located on ECL2. In summary, 
l2CA5 is shown to stain all six chimeras equally well, as expected, while 6H12, 2A8 and 
l3F2 only show positive staining for hBLTl, BlC7 and BlC29. 
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Figure 6: Flow Cytometric Analysis of Species Specific Monoclonal Antibody. 
Flow cytometry utilizing three cell lines is shown: 300.l9 parental cells (solid line), 
300.l9 cells expressing hBLTl (dotted line) and 300.l9 cells expressing mBLTI (dashed 
line). a) Both the cell lines expressing HA-tagged receptor demonstrated positive 
staining for 12CA5, while 300.l9 parental cells are negative. b) HA-tagged hBLTl only 
showed positive for 6H12 (human specific BLTI mAb) , where the 300.l9 cells 
expressing mBLTl as well as parental 300.19 showed negative. c) HA-tagged mBLTl 
only showed positive for 6Bl (murine specific BLTI mAb), where the 300.19 cells 
expressing hBLTI as well as parental 300.19 showed negative. 
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Figure 7. Strategy for Random Chimeragenesis of hBLTl and mBLTl. hBLTl was 
first cloned into the pcDNA3.l vector at Nhe I and Hind III restriction sites. mBLTl was 
next cloned into above construct at EcoR I and Not I sites The pcDNA3.1 vector 
containing hBLTl and mBLTl sequence was linearized by BamHl. The linerized 
plasmid (750 ng) was transformed into DH5a and TOP 10 ~. coli strains. Only plasmids 
encoding chimeric receptors form colonies. 
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h325,m326 
Total=351 
h311,m312 
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B1C15 B1C29 B1C25 
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h238,m240 h228, m230 h143,m146 
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B1CB 
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Figure 8: Cartoon Representation of BLTI Chimeric Receptors. Chimeric receptors 
resulting from random chimeragenesis were sequenced to determine the exact region of 
crossover between hBLTl and mBLTl. Since hBLTl was on the 5' end of the coding 
region, all chimeras begin with hBLTl. Wild-type hBLTl is shown in pink:. Wild-type 
mBLTl is shown in blue. Chimeras between hBLTl and mBLTl represented by the both 
colors. The total amino acid length of the chimera and at which amino acid residue of 
hBLTl ends and mBLTl begins is noted under each construct. 
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Figure 9: Epitope Mapping for hBLTl and mBLTl Monoclonal Antibodies: HEK-
293 cells were transiently transfected with HA tagged hBLTl (green line), B 1 C7 (blue 
line), BIC29 (red line), BIC22 (pink line), BIC8 (light green line) or mBLTl (light blue 
line). 12CA5 and several hBLTl monoclonal antibodies were used to stain these transient 
transfections. 12CA5 is a positive control for each transfection (a and c). Staining with 
6H12 is shown in b and d, where only hBLTl , BIC7 and BIC29 demonstrate positive 
staining, while BIC22, BIC8 and mBLTl are negative. Quantification of the percentage 
of positive cells for 12CA5 staining and two different hBLTl antibodies is shown in f. 
Once again, 12CA5 is shown to stain all six equally well, while 2A8 and 13F2 only show 
positive staining for hBLTl , BIC7 and BIC29. 
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Characterization of hBL Tl Monoclonal Antibodies 
To test whether these monoclonal antibodies could bind primary human cells, a 
blood sample was taken and the neutrophils were isolated and stained with a sampling of 
the monoclonal antibodies. 300.19 cells expressing hBL Tl were used as controls in the 
same experiment. All eight antibodies stained 300.19 cells expressing hBLTl very well, 
however, only five of the eight stained primary human neutrophils. To test whether this 
staining difference was due to differential glycosylation status of hBLTl in murine B 
cells versus human primary neutrophils cells, a deglycosylation mutant of hBLTl was 
generated by standard site directed mutagenesis protocol (Jala et al), in which the two 
glutamine glycosylation sites were mutated to glutamate (N2Q and NI64Q). A stable 
300.19 cells expressing N2Q- NI64Q-hBLTl (hBLTI-DG) was generated and tested for 
antibody specificity. A panel of antibodies were used to stain the 300.19 cells expressing 
the deglycosylation mutant of hBLTl and as seen in Table 1 all the antibodies tested 
stained the deglycosylation mutant at equal or better levels than the wild-type hBLTl 
line. 
Differential Expression of Murine BL Tl Detected by Monoclonal mBL Tl 
Antibodies 
Using the same hBLT1/mBLTl chimeras, it was shown that the murine BLTI 
monoclonal antibodies were also specific for the ECL2 region of the protein (data not 
shown). Using these mBLTl monoclonal antibodies, the expression pattern of murine 
BLTI was demonstrated by flow cytometry. BLTI-I- mice served as a negative control to 
determine the precise expression in primary cells from mice. We also analyzed the 
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expression of BLTI in BLT2-/- mice as the BLTI promoter is located in the BLT2 
coding region and the expression pattern ofBLTI may be altered in BLT2-/- mice. Thus, 
the mAbs are a valuable tool to examine this aspect of BLTI regulation as this will 
become important for studies described in Chapter III. We analyzed the expression of 
mBL Tl in various primary cells isolated from murine blood, bone marrow, lymph nodes 
and spleen. 
a) Neutrophils: 
The expression of BLTI on neutrophils from murine blood, bone marrow, lymph 
nodes and spleen of wild-type, BLT2-/- and BLTI-/- mice is shown in Figures 10 and II. 
The gating strategy by forward and side scatter for neutrophils is shown in Figure 10a for 
blood, Figure 10c for bone marrow, Figure 11 a for spleen, and Figure 11 c for lymph 
nodes. This gated population was further analyzed for expression of GR-I-FITC, a major 
neutrophil marker (Figures lOb, lOe, 11 b, 11 e), and GR -1 + cells are analyzed for the 
expression of BLTI (Figures lOc, lOf, lIc, 11 f). BLTI-/- cells are represented by a red 
line, BLT2-/- by a blue line and wild-type (BLTl/BLT2+/+) mice by a green line. The 
highest expression of BL Tl was seen in blood and the bone marrow neutrophils (Figure 
10c and 10f). Though few neutrophils are present in the spleen and lymph nodes, they 
showed positive staining for BLTI in GR-l + cells in Figures 11 c and 11 f suggesting the 
presence of mBL Tl at low levels compared to blood and bone marrow cells. 
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Figure 10: BLT1 Expression on Neutrophils from Murine Blood and Bone Marrow. 
Whole blood of mice was collected from C57/B16 mice by cardiac puncture. Tibias and 
femurs were removed from mice and flushed with RPM!. The bone marrow was 
uniformly resuspended, filtered and washed. 1 X 106 bone marrow cells were taken for 
analysis. 50 JlL of blood was taken directly for analysis. Blood (a,b and c) and bone 
marrow (d,e and f) were stained with 3D7 and GRI-FITC. Neutrophils were gated using 
characteristic forward and side scatter in a and d. Cells which stained positively for the 
GRI-FITC marker were gated in band e. GRI-FITC positive neutrophils were analyzed 
for their expression of BLTI in c and f. Staining for BLTI -/- mice (red line), BLT2 -/-
mice (blue line) and BLTlIBLT2 +/+ mice (green line) showed BLTI -/- mice stain 
negatively with 3D7, while BLTlIBLT2 +/+ and BLT2 -/- both stain well in both bone 
marrow and blood. 
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Figure 11: BLTI Expression on Neutrophils from Spleen and Lymph Nodes. Spleen 
and lymph nodes were removed from C57/Bl6 mice and single cell suspensions were 
made by passage through nylon mesh. 1 X 106 spleen and lymph node cells were taken 
for analysis . Spleen cells (a, b and c) and lymph node cells (d, e and f) were stained with 
3D7 and GRI-FITC. Neutrophils were gated using characteristic forward and side scatter 
in a and d. Cells which stained positively for the GRI -FITC marker were gated in band 
e. GR 1-FITC positive neutrophils were analyzed for their expression of BL T 1 in c and f. 
Staining for BLTI -/- mice (red line), BLT2 -/- mice (blue line) and BLTl /BLT2 +/+ 
mice (green line) showed the background staining for BLTI -/- mice with 3D7 increased, 
while BLTlIBLT2 +/+ and BLT2 -/- both demonstrated positive staining for BLTl. 
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b) Eosinopbils: 
Eosinophils were also found to express BLT1 at high levels in the blood and at 
lower levels in bone marrow, spleen and lymph nodes. The gating strategy for 
eosinophils is shown in 12a (blood), 12d (bone marrow cells), 13a (spleen) and 13d 
(lymph nodes) where all cells were plotted for GR-1-FITC expression on the y-axis and 
side scatter on the x-axis. Cells which were GR-1-intermediate and showed a high side 
scatter were gated as eosinophils. The gate was then analyzed in 12b, 12e, 13b and Be 
for the expression of Siglec-F-PE, which is a specific marker for murine eosinophils. 
Siglec-F positive cells were finally analyzed for the expression of BLTI in 12c, 12f, 13c 
and 13f. In summary, expression ofBLTl is high in the blood (Figure 12c) and is readily 
detectible in the bone marrow, spleen and lymph nodes (Figure 12f, 13c and 13t). 
c) Macropbages: 
Macrophages were analyzed to detect the expression of mBLTl in the bone 
marrow, followed by the blood, spleen and lymph nodes of wild type, BLT1-/- and 
BLT2-/- mice. The gating strategy is shown in 14a (blood), 14d (bone marrow), 15a 
(spleen) and 15d (lymph node), where all cells were initially plotted by forward and side 
scatter. The gated cells were then analyzed by fluorescence of CD 11 b-FITC and CD16-
PE (Figure 14b, 14e, 15b and 15t). CDllb is a marker for macrophages and neutrophils 
which were separated by the forward and side scatter. Those cells which showed high 
fluorescence for CDllb and CD16 were gated (Figure 14b, 14e, 15b and 15t)and 
analyzed for the expression ofBLTI (14c, 14f, 15c and 15t). The highest expression of 
BLT1 in macrophages was seen in the bone marrow (Figure 14t). BLT1 expression was 
also present in the blood and even though macrophages are a rare population in the spleen 
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and lymph node, positive staining was seen in those locations as well. It was observed 
that the expression of mBLTl decreased in bone marrow of BL T2-/- mice compared to 
wild-type mice. Whether this difference has any functional impact needs to be studied 
further. Analysis of macrophages with intermediate levels of CD 16 and CD 11 b staining 
showed not detectable BL Tl expression (Figure 16). 
d) Natural Killer Cells: 
The expression of BLTI was analyzed on natural killer cells (FigureI7) from 
blood, bone marrow, spleen and lymph nodes. Natural killer cells were gated from the 
side and forward scatter analysis as shown in 17a. The gated cells were then analyzed by 
NK1.1-PE, a natural killer cell marker, and CD3-FITC (17b) and the NK1.1 + CD3- cells 
were taken as natural killer cells and were analyzed for their expression ofBLTI in blood 
(17c), and bone marrow (17d). Natural killer cells that express the T cell marker CD3 are 
termed natural killer T cells. Using a similar gating strategy as NK cells, natural killer T 
cells were tested for BLTI expression. NKT cells were gated by forward and side scatter 
in 17a with the same gate as NK cells. The gated cells were again analyzed with NK1.l-
PE and CD3-FITC, but the cells which stained for both CD3 and NK1.l were taken as 
NKT cells. The expression in blood (17e) and bone marrow (17f) is shown and again, no 
positive staining was seen for BLTI in the sites tested. 
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Figure 12: BLTI Expression on Eosinophils from Blood and Bone Marrow. Whole 
blood cells and bone marrow cells were isolated from C57/Bl6 mice as described in 
Figure legend 11. Blood (a,b and c) and bone marrow (d,e and f) were stained with 3D7, 
GRI -FITC and Siglec-F~PE. Eosinophils were gated as ORl intennediate and S C high 
in a and d. Cells which stained positively for the Siglec-F-PE marker were gated in band 
e. Siglec-F positive eosinophils were analyzed for their expression of BLTI in c and f. 
Staining for BLT I -1- mice (red line), BLT2 -1- mice (blue line) and BLTlIBLT2 +1+ 
mice (green line) demonstrated a large increase in staining of BLT 1 IBL T2 +1+ and BLT2 
-1- mice over BLTI -I· mice in the blood. The background staining of BLTI -1- mice 
increased in the analysis of bone marrow, but positive staining is visible for B TlIBLT2 
+1+ and BLT2 -1- mice. 
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Figure 13: BLTI Expression on Eosinophils from Spleen and Lymph Nodes. Spleen 
and lymph nodes were isolated as described in Figure 12 legend. Spleen cells (a,b and c) 
and lymph node cells (d,e and f) were stained with 3D7, GRl -FITC and Siglec-F-PE. 
Eosinophils were gated as GRl intermediate and side scatter high in a and d. Cells which 
stained positively for the Siglec-F-PE marker were gated in b and e. Siglec-F positive 
eosinophils were analyzed for their expression of BL T 1 in c and f. Staining for BLTI -1-
mice (red line), BLT2 -I· mice (blue line) and BLTI /BL 2 +1+ mice (green line) showed 
background staining for BLTl -/- mice with 3D7 increased, while BLTlIBLT2 +1+ and 
BLT2 ·1· both demonstrated positive staining for BLTl. 
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Figure 14: BLTI Expression on CDllb High and CD16 High Macrophages from 
Blood and Bone Marrow. Blood (a,b and c) and bone marrow (d e and f) were tained 
with 3D7, CDllb-FIT and CD16-PE. Macrophages were gated by characteristic 
forward and side scatter (a and d) . Cells which stained CD 11 b high and CD 16 high were 
gated (b and e). CDllb high and CD16 high macrophages were analyzed for their 
expression ofBLTl (c and f) . Staining for SLTI -1- mice (red line), BLT2 -1- mice (blue 
line) and BLTI /BLT2 +1+ mice (green line) demonstrated a noticeable increase in 
taining of BLT1IBLT2 +1+ and BLT2 -1- mice over BLTI -1- mice in the blood. A 
definite increase in BLI1 staining was seen in bone marrow for BLTlIBLT2 +1+ mice 
and a moderate increase in BLT2 -1- mice. 
46 
104 b c 
C 800 80 
CD 103 >< :r: 
.0 ro CD 0600 ~ ~ 60 
- (f) 8102 o..(f) 0 
Cf) <fl. 40 
101 
20 
01 10° 
0 200 400 600 800 1000 100 101 102 103 104 10 100 1000 10000 
FSC-H CD16 BLT1 
CD 1000- d 10' f 
"0 e 
0 800 80 
Z 103 ~ I 
.0 
....c: 0600 ' 
..... ~ 60 (f) 8102 0 o..(f) 
0 
0 
E 400 40 
>. 101 ' 
.-oJ 200 20 
0" 100 
0 10° 101 102 103 104 10 100 1000 10000 
CD16 BLT1 
Figure 15: BLTI Expression on CDllb High and CD16 High Macrophages from 
Spleen and Lymph Nodes. Spleen cells (a,b and c) and lymph node cells (d, and f) 
were stained with 3D7, CDllb-FITC and CD16-PE. Macrophages were gated by 
characteristic forward and side scatter in a and d. Cells which stained CD 11 b high and 
CD 16 high were gated in band e. CD 11 b high and CD 16 high macrophages were 
analyzed for their expression of BLTI in c and f. Staining for BL Tl -/- mice (red line), 
B T2 -/- mice (blue line) and BLTlIBLT2 +/+ mice (green line) showed high 
background staining for BLTI -/- mice and an increase in staining is seen in macrophages 
from BL T IIBL T2 +/+ and BL T2 -/ - mice. 
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Figure 16: Lack of Detectable BLTI Staining on CDUb Intermediate and CD16 
Intermediate Macrophages. Blood (a,b and c), bone marrow (d), spleen cells (e) and 
lymph node cells (f) were stained with 3D7, CDllb-FITC and CD16-PE. Macrophages 
were gated by characteristic forward and side scatter in a. Cells that were CD 11 b 
intermediate and CD 16 intermediate were gated in b. CD 11 b intermediate and CD 16 
intermediate macrophages were analyzed for their expression of BLTI in c,d,e and f. 
Staining for BLTI ./- mice (red line), BLT2 -/- mice (blue line) and BLTl /BLT2 +/+ 
mice (green line) demonstrated no detectable expression of S LT I on CDIlb intermediate 
and CD 16 intermediate macrophages in any sample tested. 
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Figure 17: Lack of Detectable BLTI Staining on Natural Killer or Natural Killer T 
Cells. Blood (a,b,c and e) and bone marrow (d and t) were stained with 3D7, CD3-FITC 
and NKl.I -PE. Natural killer and natural killer T cells were gated by characteristic 
forward and side scatter in a. Cells which stained NKl .l positive and CD3 negative and 
cells which stained NKI.2 positive and CD3 positive were gated in b. NK l .l positive 
natural killer cells were analyzed for their expression of BLTl in blood (c) and bone 
marrow (d) . NKl.l and CD3 positive natural killer t cells were analyzed for their 
expression ofBLT I in blood (e) and bone marrow (t) . Staining for BLTI -/- mice (red 
line), BL T2 -/ - mice (b lue line) and BL T lIBL T2 +/+ mice (green line) demonstrated no 
detectable expression of BLTl on natural killer cells or natural killer T cells in blood or 
bone marrow. 
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e) B cells: 
BL Tl had not been identified on B cells previously and our tests showed no 
expression on B cells at any site tested. The gating strategy is shown in Figure ISa from 
all cells being shown by forward and side scatter. The gated cells were analyzed for 
their expression of B220, a B cell marker (Figure ISb). B220 positive cells were 
analyzed for their expression of BLTI in blood (lSc), bone marrow (lSd), spleen (ISe) 
and lymph nodes (lSf). There was no detectable expression of mBLTl observed in B 
cells from any locale. 
f) T cells: 
Expression of BL Tl has been shown in populations of activated T cells. Analysis 
of T cells in various sites in the mouse, however, demonstrated no detectable expression 
ofBLTI on T cells at any site tested. The same forward and side scatter gate was used in 
(Figure 19a) as for the B cells, but the gated cells were tested for their expression of 
CD3-FITC, a T cell marker, (Figure 19b). CD3 positive cells were again analyzed for 
their expression of BL TI in blood (Figure 19c), bone marrow (Figure 19d), spleen 
(Figure 1ge) and lymph node (Figure 19f). 
Recent studies show that activated effector T cells, but not naIve T cells express 
BL Tl at detectible levels (l6). It is apparent that the T cells analyzed in our unstimulated 
mice are not effector cells. To test for BLTI expression on activated T cells, we received 
CDS+ effector and central memory T cell cultures from the Gelfand laboratory. These 
cells were stained with the naked 3D7-mBLTl antibody along with CDS-PE or CD62L-
PE. CDS+ effector T cells should stain highly with CD62L, while central memory cells 
stain CD62L low. In Figure 20, staining with 3D7-mBLTl and CDS shows a definite 
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increase in staining for effector T cells (31 % in a) when compared to central memory T 
cells (0.3 %). A similar result is seen upon staining with 3D7-mBLTI and CD62L, 
where effector T cells are CD62L high and demonstrate 28% positive staining for BLTI, 
while central memory T cells are CD62L low and shows only a background level of 0.4% 
positive staining. In studies carried out in Dr. Gelfand's laboratory using the biotinylated 
3D7-mBLTI antibody, dexamethasone was shown to up-regulate the expression ofBLTI 
in CD8+ effector and but not in CD8+ central memory T cells (Figure 21). Furthermore, 
the increase in expression was correlated with increased functional activity as measured 
by calcium mobilization and ERK-activation (data not shown). 
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Figure 18: Lack of Detectable BLTI Staining on B cells. Blood (a,b and c), bone 
marrow (d), spleen cells (e) and lymph node cells (f) were stained with 3D7 and B220-PE. 
B cells were gated by characteristic orward and side scatter (a). ells which stained 
B220 po itive were gated in (b). B220 positive B cells were analyzed for their expression 
ofBLTl (c,d,e and f). Staining for BLTI -/- mice (red line), BLT2 -/- mice (blue line) 
and BLTl /BLT2 +/+ mice (green line) demonstrated no detectable expression ofBLTl 
on B cel ls in any sample tested. 
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Figure 19: Lack of Detectable BLTI Staining on Resting T cells. Blood (a,b and c), 
bone marrow (d), spleen cells (e) and lymph node cells (f) were stained with 3D7 and 
B220-P . T cells were gated by characteristic forward and s'de scatter in a. Cell which 
stained CD3 positive were gated in b. CD3 positive T cells were analyzed for their 
expression ofBLTl in c,d,e and f. Staining for BLT l -/- mice (red line), BLT2 -/~ mice 
(blue line) and BLT l /BLT2 +/+ mice (green line) demonstrated no detectable expression 
of BLTl on T cells in any sample tested. 
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Figure 20: BLTI is Expressed on CD8+ Effector, but not on Central Memory T cells. 
CD8+ T cells cultures were prepared and shipped to our laboratory. CD8+ effector and 
central memory T cells were stained with unconjugated 3D7 and either CD8-PE or CD-
62L-PE. Both populations are CD8+, but effector T cells are CD62L low and central 
memory T cells are CD62L high. CD8 or CD62L staining are shown on the y-axis and 
3D7 staining is shown on the x-axis. CD8+ efTector T cells demonstrate positive staining 
for BL T 1, but not CD8+ central memory T cells. 
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Figure 21: Dexamethasone Up-regulates BLT1 on T Effector but not T Central 
Memory Cells. (a) surface expression ofBLTl on CD8+ central memory T cells (T 'M), 
DEX-treated TCM, CD8+ effector T cells (TEFF) and BLTl -deficient DEX-treated T Fr 
cells. DEX (100nM) was added in culture media during differentiation of T EFF, T M or 
BLTl -deficient T FF cells. Cells after 7 days of culture were stained with biotinylated 
3D7, followed by APe-conjugated streptavidin. Staining of these cells with isotype 
control showed similar staining as TCM cells. (b) Surface expression of B Tl on TEFF 
cells treated with different doses of DEX (0-1000 nM). The data shown a1' 
representative of three independent experiments. 
55 
DISCUSSION 
This section describes the generation and characterization of monoclonal 
antibodies against both human and murine BLT1. Membrane proteins in general and 
GPCRs in particular are known to be difficult immunogens for making monoclonal 
antibodies. Use of knock out mice for generating high affinity antibodies to membrane 
proteins such as L-selectin was highly successful (74). The general presumption being 
that in knock-out animals the protein becomes non-self and therefore, immunogenic. The 
immunization scheme of using 300.19 cells to express the protein of interest and the use 
of BLT1-/- mice worked well to produce three sets of antibodies: those to HA-tag, 
mBL T1 and hBLT1. Though we intended to produce antibodies that were cross-reactive 
between human and murine BLT1, the resulting antibodies were found to be specific for 
the immunized form of BLT1. Thus, despite the two proteins being highly homologous, 
we generated antibodies specific to the unique regions of the receptors. Interestingly, 
while the antibodies did not cross-react, both the human and murine BLTI antibodies 
were specific for the ECL2 of the respective form of BLTI. This result may be placed in 
the context that ECL2 is the largest of the extra cellular loops and therefore likely to have 
contributed most epitopes. The fact that nearly 30 different antibodies for human BLTI 
as well as the 8 antibodies for murine BL Tl were all reactive against the ECL2 region 
suggests that this region is probably immuno-dominant. In this context, it is interesting to 
note that the most diverse region between the human and the murine BLT1 is ECL2. 
While the mBLT1 and hBLT1 display ~79% homology the ECL2 region as shown below 
is only 41.7% identical with only 10 identical residues out of24. 
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hBLT1-AYRTVVPWKTNMSLCFPRYPSEGH 
. . .. 
.. . .. 
mBLT1-VYRTVK-WNNRTLICAPNYPNKEH 
This result raises the question whether all of these antibodies may be against a 
single epitope and originated from the same clone. However, it was found that antibodies 
of the classes IgG 1, IgG2a and IgG2b subtype were found in the analysis of 
representative antibodies (data not shown). This demonstrates that these antibodies 
originated from separate and distinct plasma cells. However, we could not reach firm 
conclusions about the specific epitopes on murine and human BLTI recognized by our 
panel of monoclonal antibodies. Further studies with additional chimeras in ECL2 region 
and peptides corresponding to this region of mBLTI and hBLTI will delineate the 
binding sites for all of the antibodies described here. 
As all the hBLTIantibodies were identified by screening with HA-tagged hBLTI 
expressing 300.l9 cells they were further tested and were reactive against RFP-fused 
hBL TI. Moreover, they also recognized hBL TI expressed in a rat basophilic leukemia 
(RBL) cell line suggesting that there are no cell type-dependent differences in epitope 
recognition for exogenously expressed BLTI. To examine the expression of BLTI in 
primary cells we stained human neutrophils and observed positive staining with most 
antibodies. However, as described in Table 1 not all hBL TI antibodies were reactive 
against human neutrophils. Since both primary and transfected cells were stained on the 
same day it is not clear why some of these antibodies did not react with human 
neutrophils. Since we used murine cells expressing the human BLTI for immunization, 
it was possible species specific differences in glycosylation status might have contributed 
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to differences in the reactivity of human neutrophils and transfected cells. However, 
when mutants of BL Tl that are defective in glycosylation were tested, all antibodies 
reacted equally well indicating no effect of glycosylation status in BL Tl epitope 
recognition. Another possible explanation for the observed result is potential 
polymorphisms in BL Tl gene; however this remains to be explored further. 
A monoclonal antibody for hBL Tl has been generated and used to show the 
expression ofBLTl in monocytes and granulocytes from human peripheral blood by flow 
cytometry (72). Minor subpopulations of CD19 and CD22 positive B cells and CD8 
positive cells showed some BL Tl staining. In their studies, binding of antibodies to 
BLTI was not blocked by adding synthetic peptides representing the extracellular loops 
of BLTI suggesting that the epitopes may have been conformation-dependant. In 
contrast, our use of chimeric receptors allowed mapping of the antibody binding site to 
the ECL2. Since the antibodies described by Sabirsh et al also displayed species specific 
reactivity, they might be binding to the similar sites in ECL2. Both antibodies were 
found to block the function of the receptors as determined by increase in EC50 for 
calcium, chemotaxis and MAP kinase activation (73). In preliminary experiments with 
partially purified 6H12 antibody, we observed ~50% inhibition of dose dependent 
calcium mobilization. Recent studies from our laboratory showed that ECL2 is a critical 
region for LTB4 binding in BLTI (12). Thus, the current demonstration that ECL2 is also 
the binding site for BLTI antibodies offers an explanation for their functional blocking 
capacity. Their potential use in the clinic, however, requires further in vitro and in vivo 
characterization. 
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Because our intent was to generate antibodies against both murine and human 
BLTl, we initiated experiments to produce murine BLTl antibodies. The anti mBLTl 
antibodies would be extremely useful in characterizing different knock-out and transgenic 
animals developed in our laboratory as well as to address specific expression patterns and 
regulation of BLTl in murine primary cells. As described in Results, we were quite 
successful and generated eight independent monoclonal antibodies for mBL Tl. L TB4 
responsive receptors have been demonstrated by function in multiple cell types of mice 
and these antibodies have allowed us to begin probing these cells for expression. In 
humans and in mice, neutrophils have been shown to be a key BL Tl expressing cell. The 
results presented here confirm that neutrophils are indeed the highest BLTl expressing 
primary immune cells. Moreover, as might be expected the BLTl-/- mice did not show 
any detectable expression of BL Tl. But more importantly, the new mBLTl antibodies 
have allowed analysis of BLTl expression in BLT2-/- mice. Since both BLTl and BLT2 
are closely linked in the genome and separated only by ~4.0 kb of intergenic region, the 
influence of disrupting one gene on the expression of the other could be quite significant. 
In this context, the data presented here shows that both in neutrophils and in eosinophils 
the BLTl expression is similar to WT mice in BLT2-/- mice. This observation is 
particularly relevant to the studies reported in Chapter III. 
Analysis of BL Tl expression in cells isolated from different tissues revealed 
interesting patterns. Neutrophils and eosinophils showed high levels of expression when 
analyzed from different tissues such as bone marrow, blood, lymph nodes and spleen. In 
contrast, the expression of BLTl in macrophages showed significant variation based on 
the tissue from which they were isolated. This may be related to maturation status of 
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macrophages. Macrophages with high CD 11 b and CD 16 expression showed significant 
BL Tl expression, whereas macro phages with low CD 11 b and CD 16 showed complete 
lack of BLTI expression. In addition, macrophages from bone marrow displayed higher 
levels of BLTI expression relative to blood monocytes. Previous studies from our and 
other laboratories have shown functional expression of BLTI in murine and human 
monocyte/macrophages. However, the current results suggest a potential for tissue and 
maturation stage-dependent regulation of BLTI in macrophages. Since macrophages 
express high levels ofBLTl in the bone marrow, low levels ofLTB4produced from bone 
marrow-derived leukocytes might act as a retention signal for these cells. We propose 
under conditions of inflammation, the balance shifts to increased tissue levels of L TB4 
and as a consequence higher systemic levels of L TB4. Indeed, increased tissue and 
systemic levels of L TB4 were reported in diverse inflammatory diseases including 
atherosclerosis and arthritis. Increased levels of L TB4 have been observed in the blood 
and synovial fluids of patients with rheumatoid arthritis (76, 77). This could then serve as 
mechanism for rapid mobilization of inflammatory cells to the site of inflammation. The 
decrease in BLTI levels in peripheral tissues could be related to the receptor activation 
and down regulation due to increased L TB4 levels. 
Although we did not detect any BLTI staining III our analysis of T or B 
lymphocytes in peripheral blood or lymph nodes, several laboratories have demonstrated 
functional expression on effector T cells. In previous studies expression of BLTI was 
observed on activated T cells and the T cells we studied were resting and unactivated 
which explains their lack of BL Tl expression. When effector and central memory CD8+ 
T cells were tested for expression of BL Tl, effector cells showed positive staining, while 
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central memory cells were completely negative. This is in line with the prevlOUS 
functional data reported by Ott et al. (78) and later by Miyahara et al. (50) who showed 
that BL T1 expression on CD8+ T cells is critical in murine models of airway hyper-
responsiveness. More recently, using the biotinylated-3D7 antibody described in this 
thesis, Ohno in Dr. Gelfand's laboratory identified that dexamethasone up regulates 
BLT1 expression in effector memory CD8+ T cells (unpublished data). A certain 
percentage of asthma patients treated with corticosteroids are insensitive to the drugs and 
in some cases might exasperate the disease. The dramatic increase in the expression and 
function of BL T1 by dexamethasone offers a potential explanation for steroid resistance 
in asthma. 
A large number of diseases have been associated with L TB4 and many would 
likely be benefited by an antibody which blocks BLT1 function. That is an ultimate goal 
of this research. What both the hBL T1 and mBL T1 antibodies allow for at this point is 
the characterization of BL T1 in disease scenarios and in pre-clinical mouse models of 
disease. For example, the mBLT1 antibodies will allow us to determine which cells 
differentially express BLT1 during the development of different diseases given the ease 
of being able to follow disease progression in mouse models. The current studies 
confirmed that neutrophils, eosinophils and macrophages express BL T1. Beyond that, 
differential regulation of BL T1 in macrophages was identified. In addition, steroid 
induced up-regulation of BLT1 levels in T cells was demonstrated. Thus, the studies 
presented are just a beginning of what could become an important area of study. This 
understanding might allow us to proceed towards treating human disease. 
61 
CHAPTER III 
NON-REDUNDANT AND CRITICAL ROLES FOR 
LEUKOTRIENE B4 RECEPTORS BL Tl AND BL T2 IN 
MOUSE MODELS OF INFLAMMATORY ARTHRITIS 
INTRODUCTION 
Inflammation 
The role of inflammation in disease processes of humans has become an 
important topic recently even prompting a cover story on TIME magazine. Many 
diseases which had been simply associated with genetics have recently been intimately 
associated with inflammation. Atherosclerosis is one such case where it had been 
thought that the disease was caused by faulty regulation of lipid metabolism, but is now 
known to be largely due to chronic inflammation. Inflammation was historically 
described by the Latin words calor, dolor, rubor and tumor which mean heat, pain, 
redness and swelling. Inflammation brings about these results by the action of cytokines, 
chemokines and other mediators with their effects on leukocytes and the vasculature (79). 
These mediators cause vasodialation, which causes the redness, heat and swelling and 
brings in inflammatory cells, which by their actions cause the pain. In the initial stages 
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of inflammation, neutrophils are the main cell type present followed by macrophages. 
These two types of immune cells form the first line of defense in infection. Either 
through additional cytokine and chemokine production, or through antigen presentation 
by dendritic cells, the adaptive immune system becomes involved at later stages and 
enables the immune system to be more focused in its attack. These cells can once again 
cause the recruitment of neutrophils and macrophages and in the case of acute infection 
cause the clearance of the infectious agent and resolve the inflammation. In chronic 
infections, the inflammation is ongoing and is not cleared. Chronic infections have been 
linked to a number of auto-immune diseases (80-84). There are several mechanisms by 
which this is thought to occur including molecular mimicry by the infectious agent (82). 
A brief overview of what auto-immune disease is and what connections have been made 
follows. 
Auto-immune diseases are conditions where an individual's immune system 
causes damage to the individual chronically. Examples of auto-immune disease are 
multiple sclerosis, systemic lupus erythematosus, myasthenia gravis and rheumatoid 
arthritis. In multiple sclerosis, the body attacks the myelin sheath around nerves which 
disrupts normal nerve function (85). In lupus, auto-antibodies are made against common 
molecules such as double stranded DNA, nucleus or phospholipids and leads to a 
multitude of problems in the joints, skin, kidneys, heart, lungs, blood or brain (86). Many 
viruses have been associated with multiple sclerosis including Epstein-Barr virus (EBV) 
(81, 83). EBV is also thought to lead to the development of systemic lupus erythematosus 
due to EBNA-l of the virus having cross-reactivity with certain lupus auto-antigens (80, 
82). 
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Rheumatoid Arthritis 
Rheumatoid arthritis is the emphasis in this thesis. Rheumatoid arthritis (RA) 
affects 2.1 million Americans, which is 1 % of the population. In RA, multiple joints are 
usually inflamed in a symmetrical pattern and usually involve the small joints of the 
hands or feet (87). Rarely, rheumatoid arthritis can even affect the joint that is responsible 
for the tightening of the vocal cords to change the tone of the voice, the cricoarytenoid 
joint (88). Though RA is a disease of mostly the joints, it does affect other parts of the 
body. RA can cause Sjogren's syndrome, which is characterized by inflammation that 
affects the glands of the mouth and eyes making them particularly dry (89). Pleuritis, or 
inflammation of the lung, also occurs in RA patients, which causes tightness of the chest 
and trouble breathing (90). Rheumatoid nodules occur under the skin around the elbows 
and fingers (89). Other secondary effects of RA are pericarditis, anemia, decrease in 
white blood cells due to enlarged spleen, and vasculitis. The main presentation of RA is 
in the joints, however. 
RA demonstrates alternating periods of flares and remission. Flares can present 
as fatigue, lack of appetite, low grade fever, stiffness, and muscle and joint aches or can 
cause red, swollen, painful and tender joints due to excessive synovial fluid production 
and, of course, intense inflammation. Remissions can occur naturally or through 
interventions. They can last a few weeks or for years. During remissions, individuals 
with RA can live a normal and healthy life. What controls this cycle of flare and 
remission is unknown, but drugs have been developed that allow remission periods to be 
more frequent and to last for a greater length of time. 
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Rheumatoid arthritis (RA) has had links to several infectious agents over the years 
including Chlamydia pneumoniae (91), periodontal flora (84) and EBV (92). Indeed, one 
of the models that will be discussed below absolutely requires the presence of a bacterial 
stimulus (mycobacteria) for the model to work properly. Absence or a lower 
concentration of the mycobacteria causes the immunization protocol to be ineffective 
(93). However, a definite connection between an infectious agent and RA has not been 
proven. 
Activation of synovial fibroblasts has been linked to infectious agents through 
Toll Like Receptors (TLRs). The activated synovial fibroblasts produce pro-
inflammatory cytokines, chemokines and matrix degrading enzymes (94). TLRs have 
been recently demonstrated to be involved in the initial stage of synovial activation (95). 
Microbial products or even RNA from necrotic cells within the synovium (96) cause 
activation of the synovial fibroblasts and subsequent release of pro-inflammatory 
cytokines and chemokines (97). Another possible initiation step involves the formation of 
immune complexes resulting from auto-antibody production. Immune complexes have 
been demonstrated to induce the production of leukotrienes by mast cells (98). This 
production was absolutely necessary in an immune complex-induced peritonitis model in 
mice. Recently, a pathway of joint inflammation involving the production of LTB4 by 
mast cells was demonstrated. The mast cell generated L TB4 activates macrophages 
leading to the production of TNF a (99). TNF a induces further production of L TB4 by 
mast cells, which generates an amplification loop for the production of L TB4 and 
persistent inflammation in the synovium. 
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Many mechanisms are potentially involved in the resolution of inflammation. 
One of these are the switch from S-LO and COX enzymes to IS-LO in leukocytes. 
Where leukotrienes and prostaglandins are pro-inflammatory, the IS-LO products called 
lipoxins are anti-inflammatory. In murine air pouch model was used to demonstrate the 
temporal manner in which this transition occurs. Injection of sterile air on days 3 and 6 
led to a significant production of prostaglandin E2 (PGE2), little L TB4 production and few 
PMN s. When TNF a was administered, a large increase in L TB4 was demonstrated that 
reached a maximum at I hour and preceded a large influx of PMN s that reached a 
maximum at 2.5 hours. The maximum amount of PGE2 was seen at this time point as 
well. A large increase in lipoxin A4 was seen by 4 hours and remained elevated while the 
number ofPMNs and level ofPGE2 was reduced (100). Lipoxins have been demonstrated 
to retard the entry of new neutrophils to the site (101), reduce vascular permeability (102) 
and stimulate macrophages to phagocytose apoptotic neutrophils (103). 
Another set of molecules that down-regulate inflammation are the resolvins. 
Resolvins are derivatives of eicosapentaenoic acid have also been demonstrated in the air 
pouch model to inhibit leukocyte trafficking to the air pouch (104). These molecules act 
directly on leukocytes and have even been demonstrated recently to bind to BL TI 
specifically to down-regulate its pro-inflammatory effects (105). As stated earlier, down-
stream effects ofLTB4-BLTI interaction are at least in part mediated through NFKB. It 
was demonstrated that resolvin El dampens NFKB signaling upon interaction with its 
receptors, ChemR23 (104), which again illustrates the importance ofBLTl in 
inflammation. 
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Treatment of RA 
There is a long list of treatments for RA. General anti-inflammatory drugs such 
as aspirin are used quite often, but more specific therapies have emerged such as anti-
TNFa treatment that has greatly advanced the treatment of RA. Non-steroidal anti-
inflammatory drugs (NSAIDs) and corticosteroids are what are commonly referred to as 
the first line drugs (106). Some examples of NSAIDs are acetylsalicylate (aspirin), 
naproxen, ibuprofen, and etodolac. NSAIDs are drugs that are used to reduce tissue 
inflammation, pain and swelling. Aspirin has been used for centuries for headache and 
other aches and pains. In higher doses than for headache, it has been shown to be 
effective in treating RA (107). In these high doses, NSAIDs have side-effects which 
include stomach upset, abdominal pain, ulcers, and even gastrointestinal bleeding. Other 
potential side effects may include damage to the liver and kidneys, ringing in the ears 
(tinnitus), fluid retention and high blood pressure. To minimize the gastro-intestinal side 
effects, NSAIDs should be taken with food and typically antacids and proton-pump 
inhibitors are used. Aspirin is a COX-I inhibitor. COX-I and COX-2 both are enzymes 
that produce pro-inflammatory prostaglandins from arachidonic acid. In an attempt to 
block prostaglandin synthesis without the gastro-intestinal side-effects, COX-2 inhibitors 
were developed. These compounds will be discussed further below. 
Corticosteroids are the other first line treatment which can be taken orally or 
directly injected into the joint (108, 109). Examples of corticosteroids are prednisone and 
methylprednisolone. Corticosteroids are more effective in reducing inflammation than 
NSAIDs and are better at increasing joint mobility. They are typically used for short 
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periods during flares or when NSAIDs are not effective. Corticosteroids are used for 
short periods due to side effects which include diabetes, weight gain, facial puffiness, 
thinning of the skin and bone, easy bruising, cataracts, risk of infection, muscle wasting, 
and destruction of large joints, such as the hips. 
First line drugs are effective in blocking inflammation and pain, but are not 
effective in stopping cartilage and bone destruction (110). For this, more specific drugs 
are necessary which are termed disease-modifying anti-rheumatic drugs (DMARDs). 
The first line drugs work quickly, but DMARDs can take months or even years to work 
effectively. Due to the slow method of action and the fact that the DMARDs must be 
tailored to specific patients, early treatment is critical in RA. Some examples of 
DMARDs are hydroxychloroquine, sulfasalazine, gold salts, D-penicillamine and 
methotrexate. Sulfasalazine and methotrexate are commonly used because they have few 
side effects. Methotrexate is the treatment of choice of the second line DMARDs (111). 
Methotrexate is an immunosuppressive drug. Most immunosuppressive drugs are only 
used in patients with severe disease or complications of RA. Methotrexate is used often 
due to the ability to adjust dosing for the patient's specific needs. 
Another type of second line drugs are biologic modifiers. One of the therapies 
that is working well and gaining acceptance in the clinic is use of anti-TNF drugs such as 
etanercept, infliximab, and adalimumab. These modifiers bind to TNF and block it from 
interacting with its receptor and, thus, blocking the robust inflammation to which TNF 
leads. TNF blockers are generally taken in combination with methotrexate which 
increases the efficacy of both treatments (112). Blocking of IL-1R with anakinra has 
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shown promise in the clinic (113). It too is commonly used in combination with 
methotrexate, but has not been as effective as the other biologic modifiers. Rituxan is an 
antibody which binds to B cells and eliminates them. It has been effective in treating RA 
in patients who do not respond to the anti-TNF therapies (114). Another treatment for 
those who do not respond to anti-TNF therapies is abatacept, which blocks the activation 
of T cells (115). 
Treatments such as use of a Prosorba column are being studied currently (116). 
The Prosorba column basically uses Protein A to bind antibody. The patient's blood is 
pumped out into an apheresis machine to separate the plasma from the blood cells and the 
plasma is passed over a Protein A column to remove the auto-antibodies present and then 
pumped back into the patient. This procedure is not currently in use, but it is being 
evaluated for effectiveness in the clinic. 
Failure of COX-2 Inhibitors in Arthritis Therapy 
One of the most effective RA treatments in recent years was the use of the COX-2 
inhibitors. These include Celebex (Pfizer), Vioxx (Merck) and Bextra (Eli-Lilly). Again, 
COX-2 inhibitors were investigated and used because COX-l inhibitors had gastro-
intestinal side effects. COX-2 inhibitors were found to have a decreased incidence of 
these side effects; therefore, these compounds were given to patients for treatment of RA. 
These patients were found to have an increased risk of myocardial infarction (117) and 
the drugs were taken off the market quickly. RA has been shown to be linked to coronary 
heart disease and cardiovascular mortality rate previously (118-122). It has been 
recognized for a half century that patients with RA die prematurely (123). The 
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proportion of these deaths attributable to cardiovascular causes range from 39% to 50% 
(124-126). One possibility is that RA leads to increases in pro-inflammatory molecules 
in the periphery such as TNFa, 1L-1~ and 1L-6 (127). Another possibility for the 
increase is the treatment of RA itself. Corticosteroids have been shown to increase the 
risk of atherosclerosis-associated cardiovascular events by five-fold in those taking high 
doses of corticosteroids (128). A number of researchers are looking into this important 
linkage between RA and heart disease. Another interesting connection to RA is a new 
insight that, while cancer incidence is identical between normal individuals and RA 
patients, cancer mortality is significantly higher in RA patients (129). Once again, the 
mechanisms are not clear, but likely include altered states of the immune system, prior 
treatments for RA and mental health. 
Mechanisms of RA 
Over and above the association of RA and heart disease already made, patients 
treated with COX-2 inhibitors had an increase in cardiovascular events compared to 
patients who did not take COX-2 inhibitors. It is obviously a complex situation involving 
many parameters that must be studied further, but one simple explanation is that blocking 
of COX-2 leads to increased production of leukotrienes. The COX enzymes compete 
with 5-LO for arachidonic acid. Blocking COX-2 could lead to increased levels of 
arachidonic acid substrate for 5-LO to produce LTA4 and thereby, LTB4. It has been 
shown in animal models that mice deficient in the leukotriene pathway or treated with 
pathway inhibitors are protected from developing atherosclerosis (43, 130). Specifically, 
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part of my work has demonstrated that loss of BL Tl leads to a significant reduction in 
plaque size in the ApoE deficient mouse model of atherosclerosis (35). 
In both RA and atherosclerosis, inflammation is the culprit of the disease process. 
In RA, inflammation leads to joint destruction which is characterized by inflammatory 
influx into the joint synovium and into synovial tissue, synovial hyperplasia, and 
abnormal cellular and humoral immune responses. Neutrophils, mast cells, T cells, B 
cells, and macrophages all play an important role in disease progression and can be seen 
in the joints of RA patients. The presence of all of these cells and the destructive results 
listed are all due to the inflammatory process. As stated above, these cells are brought to 
the site by cytokines, chemokines and other inflammatory mediators such as fMLP and 
complement fragments. The complex interaction of these molecules and the cells that 
produce them must be understood for treatment of the disease to progress. 
Cytokines are small proteins that are released from cells, usually upon activation, 
that modulate cells for particular tasks by binding specific receptors. Cytokines can work 
in an autocrine manner where they act directly on the cell that produced them, a paracrine 
manner where they act on cells that are close in proximity or in an endocrine manner 
where they act on cells distant to the source of the production. They are grouped by 
structure into the hematopoietins, interferons, immunoglobulin superfamily, TNF family 
and others. Cytokines are categorized as inflammatory or anti-inflammatory, but this is 
an over-simplification. Since many cytokines are released in most situations, the effect 
they have on a cell depends on the other factors present in the system. Many cytokines 
have been implicated in RA including IL-2, IL-6, IL-I2 and IL-I8 as positive regulators 
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and IL-4 and IL-10 as negative regulators of disease (131-133). Most importantly, TNFa 
and IL-1~ have been shown to be intimately involved in RA (134) and blocking these 
cytokines has been particularly effective in the clinic in treating RA (135, 136). 
Chemokines are a sub-group of cytokines and include small proteins, 
anaphylatoxins, bacterial proteins (fMLP), and lipids. Of the small protein chemokines, 
there are many groups such as the ELR+ CXC, ELR- CXC, CC and CX3C chemokines. 
These are grouped based on characteristic cysteines that these proteins contain which in 
tum define the receptors that they bind. MCP-1 (137), CCL5 (138, 139), CXCL8 (140), 
CXCL12 (141) and many other chemokines have been shown to be important for 
recruitment of cells to the synovium in RA. Quite potent lipid chemokines also exist 
which include the prostaglandins, platelet-activating factor, and leukotrienes. These lipid 
mediators are quickly produced upon cell stimulation because no transcription or 
translation is needed to produce them. The enzymes needed to produce them are always 
present and the substrate needed is found in the cell membrane. 
Mouse Models of Arthritis 
Models of arthritis have allowed for the elucidation of which cytokines, 
chemokines and other molecules are important in RA. Commonly used models include 
streptococcal cell wall-induced arthritis, collagen-induced arthritis and the KlBxN model. 
The streptococcal cell wall-induced arthritis model is typically done in rats and involves 
the i.p. injection of cell wall components of Group A streptococci. This model is 
preferential for females and leads to recurrent cycles of inflammation in the joints (142, 
143). The pathology is similar to RA in the joints. Two very important models ofRA in 
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mice are the collagen-induced arthritis and the KlBxN models of arthritis in mice. 
Collagen-induced arthritis (CIA) has been the most widely used model of arthritis 
initiated by intradermal immunization with type II collagen (144). The immunization 
protocol varies due to a difference in susceptibility of the strains of mice, which is 
thought to be due to MHC class linking. DBA/l (H-2q) and BI0-RIll (H_2f) mice 
develop disease following immunization with collagen in Complete Freund's Adjuvant 
(CF A) for the first injection and using incomplete Freund's adjuvant (IF A) for the 
booster two to three weeks later. CIA in mice has been shown to have several features in 
common with human RA (145). In particular, the cytokine requirement and the effects of 
cytokines on the development and progression of the disease appear similar to human 
RA (146). In this regard, TNF-a and IL-IP appear critical in the development and 
progression ofRA (134). IL-2, IL-6, IL-12, and IL-18 act as positive modulators and IL-
4 and IL-I0 are negative modulators of the disease activity (131-133). 
Two KlBxN mouse models of RA have attracted significant attention in recent 
years (147, 148). The KlBxN model based on a T cell receptor (KRN) transgenic mouse 
which produces a T cell repertoire that recognizes and makes auto antibodies to the 
ubiquitous glycolytic enzyme, glucose-6-phosphate isomerase (GPI) and develops an 
aggressive form of arthritis (149). In this case disease may also be transferred with serum 
or purified antibodies. Disease development in this model is T and B cell independent 
while neutrophils and mast cells are required for joint inflammation (150, 151). Within 
CIA models and the KlBxN model, a prominent role for L TB4 in arthritis has been 
demonstrated. 
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Role of Leukotriene B4 Receptors in Arthritis 
A role for L TB4 in rheumatoid arthritis was suggested by several observations 
over the past two decades. Neutrophils from RA patients undergoing methotrexate 
therapy displayed both acute and chronic suppression of L TB4 synthesis ex vivo (152). 
This means that part of the efficacy of methotrexate therapy is likely due to this reduction 
in LTB4 production in patients. In a recent study, a significant increase in the mRNA 
levels of BLTI and BL T2 was seen in the joint tissues and cells from RA patients relative 
to OA patients suggesting a role for these receptors in RA (153). 
Targeted deletions in, or use of antagonists in, the leukotriene biosynthesis 
pathway as well as deletions of the L TB4 receptors themselves have allowed for a fuller 
understanding of the role LTB4 has in arthritis (Table 3). Much of the early data were 
provided by antagonists. In 1995, it was seen that the LTB4 receptor inhibitor CP-
105,696 was able to greatly reduce disease severity in an IL-l a accelerated CIA model 
(154). Two more LTB4 receptor antagonists were used in the IL-la accelerated CIA 
model with similar results (155). In an LPS accelerated CIA model, the L T A4H inhibitor 
SA6541 was used and reduced the severity of disease in that study (156). Data utilizing 
mice deficient in the leukotriene biosynthesis pathway in models of arthritis quickly 
followed. FLAP knock-out mice were put through the IL-la accelerated CIA model and 
found to have a 73% reduction in disease severity, which was associated with a 23% 
decrease in disease incidence. FLAP heterozygous mice were shown to have a 37% 
decrease in disease severity and a similar decrease in disease incidence as the FLAP 
knock-out mice, suggesting that FLAP is a potential drug target (157). Though this 
74 
pathway looked like a good target for arthritis treatment, attempts to use the antagonists 
in clinical trials of arthritis often failed to improve RA. 
Mouse Strain Model of Arthritis Experimental Results References 
DBA/ILacJ IL-l accelerated Complete protection against disease development by (154) 
CIA administration of BL Tl antagonist CP-105,696 
DBA/I IL-I Accelerated A 38% reduction III disease severity by (155) 
CIA administration of BLTl antagonist LY29311lNa or 
CGS25019C 
DBAl1 LPS-accelerated Reduced severity of disease by administration (156) 
CIA of L T ~H inhibitor SA6541 
DBAl1 IL-18 accelerated 5-LO inhibitor MK-886 reduced the severity of (99) 
CIA disease 
FLAP-I- lL-I Accelerated Reduced incidence and severity of disease in FLAP- (157) 
DBAIl CIA 1- mice relative to WT mice 
C57BI/6 KlBxN Complete protection by preventive (158) 
administration and reduced severity by 
therapeutic treatment with 5-LO inhibitor L-
739,010 and with BLTl antagonist CP-I05,696 
BLT1-/- and CIA Complete protection from disease development (21 ) 
BL T1/BL T2-/- in BLT1-/- and BL T1/BL T2-/- mice. Similar 
C57BI/6 levels of auto antibody (anti-C II) production in 
receptor deficient animals 
5-LO-/- and KlBxN Complete protection from disease development (151 ) 
LTA4H-/- in 5-LO-/- and LTA4H-/- mice. Adoptive transfer 
C57BI/6 of WT neutrophils is sufficient for disease 
development in 5LO-/- mice 
BLT1-/- KlBxN Complete protection from disease development (158) 
C57BLl6 in BL T1-/- mice. Adoptive transfer of WT 
neutrophils is sufficient for disease 
development in BLT1-/- mice 
Recent data has renewed interest in the L TB4 pathway as a target in arthritis. 
Chen et al. showed that neither 5-LO nor LTA4 hydrolase knock-out mice develop 
disease in the KlBxN model, while LTC4 synthase knock-out mice develop full disease. 
Prophylactic treatment with a 5-LO antagonist also completely blocked disease from 
occurring in wild-type mice. They went on to show in mast cell and neutrophil transfer 
experiments that neutrophils are the primary source of L TB4 in KlBxN arthritis (151). 
Using the BLTI knock-out animals, Luster's group showed a critical role for BLTI in 
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KJBxN arthritis (158). BLTI-/- mice do not show any signs of arthritis. Adoptive 
transfer ofneutrophils from wild-type mice restored disease in these mice but most of the 
recruited neutrophils in the synovium were BLTI negative suggesting that BLTI is 
required only for initiation of joint inflammation but not maintenance. CP-I05,696 was 
also shown to block disease occurrence in this model (158). Our studies with BLTI and 
BL TlIBL T2 deficient mice in a CIA model also suggested a critical role for BL Tl in 
arthritis. Both these mice showed similar levels of anti-collagen antibody levels 
indicating normal immune response to collagen but complete absence of joint 
inflammation (21). 
These data demonstrate a need for the development of strategies to block the 
actions of LTB4 in RA. In fact, a recent clinical trial was performed with BIIL-284 
which is claimed to be an antagonist of both BLTI and BLT2. It was found in this study 
that the antagonist did improve the disease in patients given the antagonist, but the results 
were not significant compared to the placebo group (159). They concluded that L TB4 
was not critical in the disease because it was only partially effective. A major problem 
with this study is the fact that the specificity of this antagonist has not been fully 
characterized. Only preliminary experiments have been done. Another problem is that 
the dosage that was used in the clinical trial was lOX less than those necessary for 
efficacy in mouse models. Specific inhibitors for BL T2 and dual inhibitors for BLTI 
and BL T2 are needed, especially since, as will be described below, BL T2 was identified 
as a critical mediator of arthritis in the present study. 
Our laboratory is currently involved in studies to produce these new antagonists. 
Using molecular modeling, we have been able to demonstrate the amino acids necessary 
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for the binding of L TB4 to BL T 1 and the residues which are required for activation of the 
receptor (12). Mutation of the residues predicted to be involved in binding resulted in 
loss of binding affinity demonstrating that predictions made from the modeling were 
likely to be correct. This useful model of BLTI has allowed us to screen compound 
libraries for novel antagonists of BL T1, which are yet to be tested (Basu et al. 
unpublished). Modeling is currently underway for BL T2 and we will be able to screen 
for novel antagonists targeting both BLTI and BLT2. In screening both receptors, we 
hope to discover dual inhibitors which would potentially be useful in treating human 
disease. 
Since the loss of BL T 1 was enough for mice to be protected from arthritis 
development, it was no surprise that BLTlIBLT2-/- mice did not develop disease (21). 
This result suggests that BL T2 might not be important in RA. However, as shown below, 
loss of BL T2 also protects mice from developing arthritis. Using the KlBxN model, we 
showed that BLT2-/- mice developed very minimal signs of disease and using bone 
marrow transfer experiments, the requirement for BL T2 expression by bone marrow 
derived cells was shown. Moreover, using assays for BL Tl expression and function, it 
was determined that BLTI is expressed and functional in BLT2-/- mice. Hence, both 
BLTI and BLT2 may be required for the occurrence ofRA. 
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MATERIALS AND METHODS 
Mice 
BLTl-l- mice on the Balb/c background were characterized and described in (59). 
BLTl-l- mice on the C57B1I6 were characterized in (21). BLTl-l- were backcrossed 9 
generations onto the DBAIl background and are described for the first time within this 
thesis. BLTlIBLT2-1- mice on the C57B1I6 background were characterized and 
described in (21). BLT2 -1- were generated at the Duke University Transgenic Mouse 
Core Facility and were subsequently backcrossed onto the C57Bl/6 background for 7 
generations. BLT2-1- mice are described for the first time in this thesis. All studies and 
procedures were approved by the Animal Care and Use Committee of University of 
Louisville Research Resources Center. 
RNA isolation and Reverse Transcription 
Total RNA was isolated from bone marrow cells (BMC) using Trizol Reagent and 
followed by mini RNeasy kit from Qiagen. Total RNA was treated with Turbo DNAase 
from Ambion to remove the traces of genomic DNA contamination from RNA samples. 
cDNA was synthesized from 250 ng of total RNA with random hexamer primers using 
Taqman Reverse Transcription reagents (Applied Biosystems). 
peR for mBL Tl and mBL T2 
mBLTl, mBLT2 and ~-2 micro globulin (control gene) genes were PCR amplified 
by HotStart Taq Polymerase (USB) using above synthesized cDNA (2 ilL per reaction) as 
template with following primers in 20 ilL total reaction volume. The peR was also 
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performed on the cDNA reaction mix that did not contain reverse transcriptase as a 
negative control (data not shown). 
mBLTl: Forward primer: 5' ATGGCTGCAAACACTACATCTCCT 3' 
mBLTI: Reverse Primer: 5'-CACTGGCATACATGCTTATTCCAC-3' 
mBLT2: Forward primer: 5' ATGTCTGTCTGCTACCGTCC 3' 
mBLT2: Reverse Primer: 5' AGGTGCAGCA CAAGTGTGGC 3' 
m~-2 micro globulin FP: 5' CATACGCCTG CAGAGTTAAG CA 3' 
m~-2 microglobulin RP: 5' GATCACATGT CTCGATCCCA GTAG 3' 
The PCR conditions used to amplify these products were as follows. The cDNA 
(2 /-11) and forward and reverse primers (7.5 pmoles) were added to PCR tubes containing 
0.2 mM dNTPs, 1.5 mM MgCh, 0.2 U of Hot start Taq DNA polymerase along with the 
PCR buffer provided with enzyme IX concentration. The PCR conditions were: template 
denaturation at 95°C for 4 min followed by 45 cycles at 95 °C for 30 sec (denaturation), 
56°C (annealing) and 72 °C for 30 sec (extension). The reaction was continued for 5 min 
to complete the extension. The expected sizes of the PCR products for mBLTI, mBLT2, 
~-2 microglobulin were 319,191,73 bp respectively. 
Calcium Flux 
Calcium mobilization was monitored in Indo-I-loaded cells stimulated with 
various concentrations of LTB4• Each experiment represents an analysis of 3 x 106 cells. 
Neutrophils were elicited with zymosan for 4 hours and macrophages were elicited for 48 
hours and were flushed from the peritoneum. They were then spun down, resuspended at 
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2 X 106/mL in PBS + 1 % BSA and loaded with 1.2 fll of pluronic acid (200 mg/ml in 
Me2S0) and 1.5 fll of Indo-l (1 mM solution) and incubated for 30 min at 37°C. After 
incubation, the cells were washed with PBS + 0.1 % BSA. The cells (2 x 106 cells/ml) 
were resuspended in Hank's balanced salt solution containing 1 mM CaCb. The response 
to various concentrations of ligand was recorded using a spectrofluorometer (F2500, 
Hitachi, San Jose, CA). 
CIA on the DBAII Background 
Complete freund's adjuvant (CFA) was prepared by mixing 100 mg of heat-
killed Mycobacterium tuberculosis (H37Ra; Difco Laboratories) in 20 ml of IF A (Sigma-
Aldrich). An emulsion was formed by dissolving 2.0 mg/ml chick ClI (ClI; Sigma-
Aldrich) overnight at 4°C in 10 mM acetic acid and combining it with an equal volume of 
CF A. ClI solution and the emulsion with CF A were always freshly prepared. Mice were 
anaesthetized with ketamine HClixylazine HCI (Sigma-Aldrich) and were injected i.d. at 
the base of the tail with a total of 100 fll of emulsion containing 100 flg of ClI and 250 flg 
of M tuberculosis. The same injection was repeated at day 21 in IF A. 
KlBxN Arthritis 
Serum from KlBxN arthritic mice was kindly donated by David Lee (Harvard 
University). Sera were pooled to assure uniformity in the injections. 100 flL of serum 
was injected i.p. on days 0 and 2 and mice were evaluated for clinical symptoms. 
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Paw and Ankle Measurement and Clinical Scoring 
Paw and ankle measurements were taken usmg a pocket thickness gauge 
(Mitutoyo). All mice were examined every two to three days following appearance of 
disease. Arthritis of each individual limb was graded using the following scoring system: 
0, normal; 1, apparent swelling and redness limited to one digit; 2, swelling in more than 
one digit; 3, severe redness and swelling of the entire paw; and 4, maximally inflamed 
limb with involvement of paw and ankle joint. The maximum score per mouse was 16. 
Mice were scored as arthritic if the clinical score was at least 2. 
Bone Marrow Transfer 
Recipient mice were irradiated with 900 rads to ablate all peripheral and bone 
marrow cells. The following day, donor mice were sacrificed and the femurs and tibias 
were removed and placed in RPMI medium. The bone marrow was flushed from the 
bones with RPMI, washed, and resuspended in PBS. The bone marrow from one donor 
mouse was used to reconstitute two recipient mice. Bone marrow was injected i.v. into 
recipient mice and the mice were housed in sterile caging for at least four weeks. Mice 
were allowed 8 weeks to engraft before they were taken for an experiment. 
Histopathology 
Upon termination of the experiment, mice were sacrificed and ankle joints were 
removed from both hind legs. Ankles were placed in buffered 10% formalin for 16 hours 
followed by transfer into 70% ethanol until samples were taken for sectioning. Ankles 
were decalcified and paraffin embedded. Joint sections (5mm) were stained with H&E 
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and examined for histological changes such as inflammation and bone destruction. 
Representative pictures were taken using a Nikon Eclipse E400 microscope. 
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RESULTS 
Characterization of BL Tl-/-, BL T2-/- and BL TIIBL T2-/- Mice 
We have previously generated BLTI-/- and BLTlIBLT2-/- mice. In the current 
studies we have generated BL T2-/- mice. The genomic locus spanning the BL Tl and 
BL T2 genes and the strategy for making individual and double KO mice is shown in 
Figure 22. Three primer PCR reactions were developed for determining the genotypes at 
the BLTI and BLT2 loci. Routinely, mice were genotyped from DNA isolated from tail 
snips using previously described procedures (21, 59). Figure 23a shows the genotyping 
of all three BL T deficient mice used in the current studies. The same genomic DNA was 
used in both PCR protocols to demonstrate clean recognition of the genotype of knock-
out mice. BLTlIBLT2+/+ PCR demonstrates only a wild-type band for both BLTI and 
BLT2. BLTI-/- PCR demonstrates a wild-type band for BLT2 and a KO band for BLTI. 
BLT2-/- PCR demonstrates a wild-type band for BLTI and a KO band for BLT2. 
BLTlIBLT2-/- PCR demonstrates a KO band for both BLTI and BLT2. BLTl/BLT2 +/-
PCR demonstrates both the wild-type and KO bands for both BLTI and BLT2. BLTI +/-
PCR demonstrates a wild-type band for BLT2 and both a wild-type and KO band of 
BLTI. BLT2 +/- PCR demonstrates a wild-type band for BLTI and both a wild-type and 
KO band of BL T2. 
Analysis of BL Tl and BL T2 Expression in Murine Bone Marrow 
In Figure 23b, RT-PCR analysis was done using RNA isolated from the bone 
marrow ofBLTlIBLT2+/+, BLTI-/-, BLT2-/- and BLTlIBLT2-/- mice. BLTl/BLT2+/+ 
bone marrow demonstrates expression of both BLTI and BLT2. BLTI-I- bone marrow 
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shows no signal for BLTl, but demonstrates BLT2 signal. BLT2-/- bone marrow shows 
no signal for BLT2, but demonstrates BLT2 signal. BLTIIBLT2-/- are negative for both 
BL Tl and BLT2 signal. 
BL Tl is Functional in BL T2-/- Mice 
Since the experiments described in Chapter II showed some difference in BLTI 
surface expression in BLT2-/- mice compared to wild-type mice, we determined the 
functional expression of BLTI in BLT2-/- mice. For this, zymosan-elicited neutrophils 
were tested for intracellular calcium release in response to L TB4. The expression of 
BLTI on the elicited neutrophils is shown in Figure 24. Any difference in BLTI 
expression between BL TIIBLT2+/+ and BLT2-/- mice is not statistically significant. 
The calcium flux response to L TB4 of wild-type neutrophils is shown in 25a. In 25b, the 
calcium flux response of neutrophils from BLT2-/- mice to LTB4 is shown and is 
virtually identical to the wild-type response if not slightly better. In 25c and 25d, the 
calcium flux response of neutrophils from BLTI-/- and BLTl/BLT2-/- mIce, 
respectively, is shown demonstrating no response at all. 
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Mouse Genomic Locus 
Ssp! DnmH I EcoR I BnmH I r:coR I Xho I Sac " Kpn l Bnmlll 
~I ____ ~ ______ ~~~~I--~----------~~~----~------~ 
I Kh 
Duml l IINOI I EcoR I 
BLT-J KO 
SSP IINotl i3am H I RcoR J Xho I Sac " Kpnl 
BLT-J &BLT-2 KO 
S~r I/Not I BumH I F,coR I Xho I B" mlll F.c()R II RnmH I 
BLT-2 KO 
Figure 22. Targeted Disruption of Leukotriene B4 Receptors. The strategy utilized to 
produce knock-out an imals for the LTB4 receptors is shown. A diagram of the locus on 
BL T I and BL T2 is shown at the top to demonstrate the regions deleted in each c nstmct. 
The targeting construct for BLT2 is shown on the bottom. The construct contain the 
same long arm fraglnent as the BLTlIBLI2 knock-out con tllct with a hort N-terminal 
tretch of BLT2 followed by an E .. p and an omycin cassette. Following neomycin, 
the remainder of the BL T2 sequence was kept due to the fact that the coding equence of 
L T2 contains the promoter of BLI1, though no transcription should occur sinc the 
neomycin cassette contains a stop sequence. 
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Figure 23. Targeted Deletions of LTB4 Receptors. (aj GenQtyping: Genomic DNA 
was isolated from mouse tails and peR was performed for both BLT! and BLT2 utilizing 
eparate three primer reactions as described in methods (b) RT PCR: Total RNA was 
isolated from Bone marrow cells (BMC) and cDNA was synthe ized from 250 ng of total 
RNA with random hexamer primers. mBLT1, mBLT2 and ~-2 microglobulin (control 
gene) genes were peR amplified and the results hown. The product fo mBLTl, 
mBLT2, ~-2 micro globulin wer 319,191,73 bp respectively. 
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Figure 24: BLTI Expression on Zymosan-elicited Neutrophils. Mice were injected 
with 1 mL of Img/mL zymosan-a i.p. Following four hours incubation, the peritoneum 
was washed with RPMI-1640 containing 2% FBS and 0.2 mM EDT A. A sample was 
taken and incubated with biotinylated-3D7 mouse monoclonal antibody and followed by 
streptavidin-APC. The cells were analyzed on BD F ACSCalibur with FL4 channel. The 
mean fluorescence values of B TI KO (blue bar), BLT2 KO (red bar) and wild-type 
(beige bar) neutrophils are shown (n=3). 
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Figure 25: Calcium Flu of Zymosan-elicited Neutrophils. Mice were injected with 1 
mL of Img/mL zymosan-a i.p. Following four hours incubation, the peritoneum was 
washed with RPMI-1640 containing 2% FBS and 0.2 mM EDTA. The cell s were washed 
with 1 X PBS + 1 % BSA and processed for calcium flux. Concentrations of L TB4 used 
were 1 nM (green), 3 nM (purple), 10 nM (orange), 100 nM (brown), 300 11M (black) and 
1000 nM (light blue). a) BLTlIBLT2 +/+ (wild type) b) BLT2-/- c) BLTI -ll d) 
BLT J/BLT2-/- (double knock out) 
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BLTI-/- Mice are Protected from CIA on the DBAll Background 
Our laboratory has shown that BL Tl is critical in the development of CIA on the 
C57B1I6 background in mice (21). To test whether BLT1 was important in the more 
commonly used model of CIA on the DBAll background, we bred our BLT1-/- mice 
onto the DBAll background 9 generations. The mice paws were measured on day 0 of 
the experiment for a baseline thickness and were measured on day 21 for a baseline 
thickness of the ankle joint. Following the booster injection of collagen on day 21, the 
mice were analyzed at least every 2-3 days for 3 parameters; clinical score, paw thickness 
and ankle thickness. Heterozygous mice for BLT1 were bred to give BLT1 +/+, +/- and -
/- mice as littermates and were immunized for the development of CIA using protocols 
described in Methods. Figures 26 and 27 are representative of two independent 
experiments. In both experiments, BLT1-/- mice were nearly completely protected from 
clinical disease development, whereas BLT1 +/+ mice demonstrated severe arthritis 
reaching a 100% incidence by day 58 of the experiment (26a). BLT1 +/+ mice started to 
show an increase in ankle thickness (27b), paw thickness (27a) and clinical score (26b) 
starting at day 24 and all these parameters continued to increase until the termination of 
the experiment at day 70. BLT1-/- mice were protected from development of any clinical 
signs of disease until day 49 when only 1 mouse showed clinical signs of disease (26a). 
There is no drastic increase seen at any point in paw thickness (27a) or ankle thickness 
(27b) in BL T1-/- mice. BLT1 +/- mice showed a definite delay in developing disease as 
compared to BLT1 +/+ mice. BLT1 +/- mice did not show any signs of disease until day 
34 and then the clinical score increased until the end of the experiment (26b). No drastic 
increases in paw thickness (27a) or ankle thickness (27b) were seen until day 63 where 
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both began to increase. Whereas +/+ mice reached 100% incidence on day 59, the +/-
mice only reached 100% incidence on the final day of the experiment (26a). On day 70, 
the difference between the clinical score of BLTI +/+ and BLTI +/- was significant (p< 
0.05). Clinical scores were analyzed by non-parametric t-test in GraphPad Prism version 
2.01. 
Protection of Both BL Tl-/- and BL T2-/- Mice from KlBxN Arthritis 
Arthritis was induced in BLTlIBLT2+/+, BLTI-/- and BLT2-/- mice on the 
C57Bl/6 background with 100 ilL of KlBxN arthritogenic serum injected i.p. on day 0 
and day 2 and were followed every 1-2 days for signs of arthritis. This experiment is 
representative of 3 experiments with BLTlIBLT2+/+ and BLT2-/- mice and 2 
experiments with BL Tl-/- mice. The results of this experiment are shown in Figures 28 
and 29. The clinical score is shown in 28b and demonstrates that BLTlIBLT2+/+ mice 
get a very severe disease. BL T 1-/- mice had a slight clinical score from day 6 to 10, but 
what little inflammation occurred resolved. BL T2-/- mice showed a similar fluctuation in 
clinical score between day 6 to 10, but a minimal amount of inflammation remained 
which is shown in 28b. In 28a, the incidence of arthritis is shown. BLTlIBLT2+/+ mice 
reach 100% incidence by day 8, BLTI-/- mice have no incidence of disease and BLT2-/-
mice have a 20% incidence of disease starting at day 13. This incidence was due to one 
BL T2-/- mouse getting arthritis in one paw as compared to BLTlIBLT2+/+ mice where 
all five mice get disease in at least two paws. In 29a, it is shown that BLTIIBLT2+/+ 
mice began to have an increase in paw thickness at day 1 and the thickness continued to 
increase until it reached a maximum at day 11. Neither the BLTI-/- nor the BLT2-/-
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mice showed any significant increase in paw thickness at any point in the experiment. 
The ankle thickness shown in 29b had similar kinetics to the paw thickness with the 
BL TIIBLT2+/+ mice beginning to increase at day 1 and reaching a maximum ankle 
thickness at day 9, while neither the BLTI-/- mice nor BLT2-/- mice showed any 
considerable increase. Representative histology is shown in Figure 30. A large influx of 
inflammatory cells was seen in the bottom left ofthe BLTIIBL T2+/+ joint section at 40X 
magnification. When the section was viewed at 400X magnification, individual 
inflammatory cells could be seen. Joint sections from BLTI-/- and BL T2-/- mice were 
almost completely devoid of any signs of inflammation. 
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Figure 26: Collagen Induced Arthritis (CIA) on DBA/1 Background: B Tl +1+ 
(blue), BLI I +1- (pink) and BLTI -1- (light blue) rnice on DBAIl back gro und were used 
in the IA mouse model. These mice were observed every 2-3 days for vi ual ign of 
arthritis. (a) Mice were considered arthritic when they demonstrated a stable clinical 
score of at least 2 (b) Clinical score was determined as described in Methods BLT t +1+ 
(n=1 3), BLI l +1- (n=7), B TI -1- (n=10) 
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Figure 27: Change in Paw and Ankle Thickness in DBA/1 CIA. BLI] +/+ (blue), 
BLII +/- (pink) and B Tl -/- (light blue) mice on DBAIl back ground were used in CIA 
model. These mice were followed every 2-3 days for increases in paw (a) and ankle (b) 
thickness using a dial pocket thickness gauge. 
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Figure 28: KlBxN Serum Induced Arthritis Model. K/BxN serum (1 00 Ill) was 
injected i.p on days 0 and 2 in BLTlIBLT2 +/+ (blue), BLT I ~/~ (red) and BLT2 -/-
(green) mice. These mice were observed every 1-2 day for v · sual signs of arthriti . (a) 
Mice were considered arthritic when they demonstrated a stable clinical score of at least 2 
(b) Clinical score was determined as described in Methods B Tt +/+ (n=13), B TI +/-
(n=7), BLI I -/. (n= 10) 
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Figure 29: Change in Paw and Ankle Thickness of BLTlIBLT2 +1+, BLTI -/., and 
BLT2 ~/~ Mice in K/BxN Arthritis. B TllB T2 +/+ (blue), B Tl -/- (red) and BLTl -
/- (green) mice were followed every 1-2 days for increase in paw (a) and ankle (b) 
thickness using a dial pocket thickness gauge. 
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Figure 30: Histology of KlBxN Ankle Joints. The ankle joints of B T1 /BL2 +/+, 
BL Tl -/- and BLT2 -/- mice from mice subjected to induction of KlBxN arthritis were 
sectioned and stained with Hand E. The images were obtained using Nikon Eclip 400 
microscope. Images at 40X magnification demonstrate infiltration of inflammatory cells 
in BLTIIB T2 +/+ mice, but not in BLI I -/- and BLT2 -/- mice. Inflammatory cells 
become more apparent at lOOX magnification. t 400X magnification, multiple 
individual inflammatory cells are seen in the BLTlIBLT2 +/+, while no inflammatory 
cells are present in the BLTl -/- and BLT2 -/- pictmes. 
96 
BLT2 is Required on Bone Marrow-Derived Cells for the Development of Arthritis 
To determine whether the presence of BLT2 is required on bone marrow-derived 
cells or other lineages, adoptive transfer experiments were undertaken. Recipient mice 
were irradiated with 900 rads to completely eliminate all bone marrow and peripheral 
blood leukocytes. The following day, bone marrow was isolated from donor animals and 
injected i.v. into the recipient mice. Mice which are congenic for the SJL subtype of 
CD45 antigen (CD45.1 or Ly5.l) were used in these experiments to distinguish 
reconstituted leukocytes from any remaining recipient leukocytes (CD45.2 or Ly5.2). 
Commercially available antibodies to these subtypes were used. The mice were tested for 
their CD45 expression to determine how well the transplantation worked. The CD45 
flow cytometry analysis is shown in Figure 31 for BLT2+/+ mice receiving BLT2+/+ 
bone marrow (31 a), BL T2-/- mice receiving BLT2+/+ bone marrow (31 b) and BLT2+/+ 
mice receiving BL T2-/ - bone marrow (31 c) and demonstrate ~ 95-98% donor neutrophils 
in the peripheral blood. Recipient mice were allowed to engraft for at least 8 weeks and 
were then started on the KlBxN serum transfer arthritis protocol. In Figures 32 and 33, 
the results of this experiment are shown. These data are representative of three 
independent experiments. The clinical scoring of these mice is shown in 32b and shows 
BLT2+/+ mice receiving BLT2+/+ bone marrow (+/+D/+/+R (blue line)) and BLT2-/-
mice receiving BLT2+/+ bone marrow (+I+D/-/-R mice (purple line)) have an almost 
identical course of disease reaching a maximum on day 9 while BL T2+/+ mice receiving 
BLT2-/- bone marrow (-/-D/+/+R mice (orange line)) show very minimal signs of 
disease. The incidence of disease is shown in 32a where it is seen that both +/+D/+/+R 
and +/+D/-/-R mice reach 100% incidence on day 7 and -/-D/+/+R mice reach 20% on 
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the last day of the experiment again due to one mouse getting disease in one paw. In 
+/+D/+/+R mice, an increase in paw thickness is seen by day 2 of the experiment and 
reaches a maximum around day 8. +/+D/-/-R mice show the same kinetics as the 
BL T2+/+ recipients demonstrating an increase in paw thickness by day 2 and reaching a 
maximum at day 7. -/-D/+/+R mice were completely protected from signs of increased 
paw thickness more than some transient increases. A similar trend as 33a is seen in 33b 
where both +/+D/+/+R and +/+D/-/-R show an increase in ankle thickness on day 2 and 
reach a maximum around day 9 and -/-D/+/+R showing no drastic increase in ankle 
thickness. Analysis of H & E staining of joint sections from these mice is shown in 
Figure 34. BL T2+/+ mice reconstituted with BL T2+/+ bone marrow and BLT2-/- mice 
reconstituted with BL T2+/+ bone marrow both show a drastic influx of inflammatory 
cells at 40X magnification. At 400X magnification, inflammatory cells are easily seen in 
these mice. BLT2+/+ mice receiving BLT2-/- bone marrow show no signs of 
inflammation at 40X magnification. The same region was taken at 400X magnification 
as the mice reconstituted with BL T2+/+ showed no inflammatory cells. 
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Figure 31: CD45 Expressjon Pattern of BLT2 +1+ and BLT2 -1- Reciprocal Bone 
Marrow Transplants. Whole blood from mice was stained with D4S. I-PE and 
D4S .2-FITC. D4S .2+ BLT2 +/+ and BLT2 -/- mice were reconstituted with CD4S. 1 + 
BLT2 +/+ bone marrow from CS7Bl/6 SJL congenic mic . D4S .1+ BLT2 +/+ mice 
were reconstituted with CD45 .2+ BLT2 . /- bone marrow. Both BLT2 +/+ and · T2 -/-
recipient of BL T2 +/+ bone marrow demon trated > 96% of peripheral neutrophils w r 
of donor origin. BLT2 +/+ recipi nts of BLT2 -I· bone marrow demon trated > 94% of 
peripheral neutrophils were of donor origin. 
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Figure 32: Reciprocal Bone Marrow Transplants Between BLT2 +f+ and BLT2 -f-
Mice in KlBxN Arthritis. BL T2 +f+ recipient mice receiving BL T2 f+ bone manow 
(+1+ DI +1+ R), BLT2 +1+ recipient mice receiving BLT2 -1- bone marrow (-1- DI +1+ R) 
and BL T2 -1- recipient mice receiving B T2 +1+ bone malTOW (+1+ DI -1- R) were 
observed every 1-2 days for visual signs of arthritis . (a) The incidence of clinical 
disease i shown demonstrating +1+ DI +1+ R (blue), 1+ DI -1- R (purple) and ·1- DI +1+ 
R (orange) Mice were considered to have disease when they reached a clinical core of 2. 
(h) Clinical score was determined as described in Method . 
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Figure 33: Change ill Paw and Ankle Thickness of Reciprocal Bone Marrow 
Transplant Mice in K/BxN Arthritis. +/+ D/ +/+ R (blue), ~/- D/ +/+ R (orange) and 
+/+ D/ -/- R (purple) mice were fo llowed every 1-2 days for increases in paw (a) and 
ankle (b) thickness using a dial pocket thickness gauge. 
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Figure 34: Histology of Ankle Joints for Reciprocal Bone Marrow Transplant Mice 
in K/BxN Arthritis Experiments. The ankle joints of were section d and tained with H 
and E. The images were obtained using Nikon Eclipse E400 microscope. Pictures at 40X 
magnification demonstrate infiltration of inflanunatory cells in BL T2 +/+ mice 
reconstitut d with BLT2 +/+ bone marrow and BLT2 -/- mice reconstituted with BLT2 
+/+ bon marrow, but not in BLT2 +/+ mice reconstituted with BLT2 -/- bone marrow. 
Inflammatory cells become more apparent at lOOX magnification . At 400X 
magnification, multiple individual inflanunatory cells are seen in the LT2 +1+ 
reconstituted with BLT2 +/+ bone marrow and BLT2 -/- reconstituted with BLT2 +/ 
bone marrow pictures, while no inflammatory cells are present in the BLT2 +/+ 
reconstituted with BLT2 ./. bone marrow. 
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BLTI and BLT2 are Non-Redundantly Required for Arthritis Development 
Kim et al. previously demonstrated that BL Tl-/- mice do not develop arthritis in 
the KlBxN model, but develop disease if they are given BLTI+/+ neutrophils (158). 
However, greater than 90% of the neutrophils in the synovium at the end of the 
experiment were all BLTI-/- as determined by CD45 phenotyping. We believe BLTI-/-
neutrophils are likely recruited to the synovium via expression of BL T2. Given that we 
have mice deficient in BLTI and BL T2, we have an excellent system to test this 
hypothesis. If the preliminary stages of arthritis require BL T I expressing neutrophils and 
the latter stages BL T2 expressing neutrophils, then reconstituting BL TlIBL T2-/- mice 
with equal numbers ofBLTI-/- bone marrow cells (which should have functional BLT2) 
and BLT2-/- bone marrow cells (which were shown above to express functional BLTI) 
should lead to development of arthritis in these mice. If this hypothesis is wrong (if 
simultaneous or sequential expression of BL TI and BL T2 is required), then no disease 
will occur. The CD45 flow cytometry analysis for BLTIIBLT2-/- mice given 
BLTlIBLT2+/+ bone marrow (35a) and BLTlIBLT2+/+ mice receiving a mixture of 
BLTI-/- and BLT2-/- bone marrow (35b) and analysis of BLTl/BLT2+/+ mice given a 
mixture ofBLTI-/- and BLT2-/- bone marrow with 3D7 and GR-I-PE (35c) is shown in 
Figure 35. All the mice used in this experiment displayed ~ 95-98% donor neutrophils in 
the peripheral blood with examples shown in 35a and 35b. Analysis of BLTlIBLT2+/+ 
which were reconstituted with a mixture of BLTI-/- and BLT2-/- bone marrow, showed 
that ~ 50% of the peripheral neutrophils arose from BLT2-/- bone marrow while the other 
50% was from BLTI-/- bone marrow in 35c. Results shown in Figures 36 and 37 are 
those generated from BLTlIBLT2+/+ or BLTIIBLT2-/- mice reconstituted with a 
103 
mixture of 50% BLTI-/- and 50% BL T2-/- bone marrow or with BL TlIBL T2+/+ bone 
marrow. Controls are shown in Figures 36 and 37 where wild-type mice were 
reconstituted with BLTI-/- or BLT2-/- bone marrow. Both BLTIIBLT2+/+ (blue line) 
and BLTIIBLT2-/- mice (red line) reconstituted with BLTlIBLT2+/+ bone marrow 
reached 100% incidence, though the BLTl/BLT2-/- recipients were delayed in reaching 
100% by four days compared to the BLTlIBLT2+/+ recipients. This showed in the 
clinical score in Figure 36b also, where BLTl/BLT2+/+ recipients reached a higher 
maximum clinical score and reached it four days sooner than the BLTlIBLT2-/- recipient 
mice. Though reconstitution with BLT2-/- bone marrow (orange line) or BLTI-/- bone 
marrow (light blue line) led to no disease, there was a definite increase in clinical score in 
both BLTlIBLT2+/+ (Pink line) and BLTIIBLT2-/- mice (green line) reconstituted with 
50% BLTI-/- and 50% BLT2-/- bone marrow peaking at day 9 for the BLTl/BLT2+/+ 
recipients and day 10 for the BLTlIBLT2-/- recipients. The fact that BLTl/BLT2-/-
recipients showed an increase in clinical score compared to BLTlIBLT2+/+ recipients is 
due in part because BL TIIBL T2-/- recipients had a 60% incidence of disease, while 
BL TlIBL T2+/+ recipients had a 40% incidence of disease, as shown in Figure 36a. In 
Figure 37a, it is shown once again that BLTIIBLT2+/+ mice reconstituted with 
BLTl/BL T2+/+ bone marrow developed arthritis quickly with an increase in paw 
thickness seen on day 2 and reaching a maximum at day 4. BLTlIBLT2-/- mice 
reconstituted with BLTlIBLT2+/+ bone marrow showed a similar maximum paw 
thickness, though the kinetics were delayed such that these mice did not reach a 
maximum until day 9. BLTlIBLT2+/+ or BLTlIBLT2-/- mice reconstituted with a 
mixture of BL Tl-/- and BL T2-/- bone marrow did not show any drastic increase in paw 
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thickness at any point. In Figure 37b, BL TIIBL T2+/+ mIce reconstituted with 
BLTIIBLT2+/+ bone marrow started to increase in ankle thickness by day 2 of the 
experiment and reached a maximum thickness at day 9. Similar to the results seen with 
the paw thickness measurement, BLTlIBLT2-/- reconstituted with BLTIIBLT2+/+ bone 
marrow reached the same maximum level of ankle thickness, though the kinetics were 
slightly delayed. A much more noticeable increase was seen in both BLTIIBLT2+/+ and 
BL TlIBL T2-/- mice reconstituted with 50% BLTI-/- and 50% BL T2-/- bone marrow. 
In Figures 36 and 37, wild-type mice reconstituted with BLTI-/- or BLT2-/- bone 
marrow are shown. In Figure 36a, no disease incidence is shown in wild-type mice 
reconstituted with either knockout bone marrow. In Figure 36b, a transient increase in 
BL Tl-/- reconstituted mice is seen that quickly wanes, while no increase is seen in 
BLT2-/- reconstituted mice. No significant increases in paw or ankle thickness were seen 
in either set of mice in Figures 37a or b. 
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Figure 35: Surface Receptor Characterization of Bone Marrow Transplant 
Recipient Mice. Whole blood was stained with CD45.1-PE, and CD45.2-FITC. 
CD45.2+ BLTlIBLT2 -/- mice were reconstituted with CD45.1 + BLTlIBLT2 +/+ bone 
marrow. CD45.1+ BLTlIBLT2 +/+ mice were reconstituted with a 50% mixture of 
CD45.2+ BLT2 -/- bone marrow and 50% of CD45.2+ BLTI -/- bone marrow. a) 
CD45.2+ BLTlIBLT2 -/- mice reconstituted with CD45.1 + BLTlIBLT2 +/+ bone 
marrow displayed > 98% of peripheral neutrophils were of donor origin . b) CD45.1 + 
BLTlIBLT2 +/+ mice reconstituted with a 50% mixture of CD45.2+ BLT2 -/- bone 
marrow and 50% of CD45.2+ BLT1 -/- bone marrow displayed > 98% peripheral 
neutrophils were of donor origin. c) Staining of the bone marrow cells with 3D7 
(mBLT1 specific monoclonal antibody) and GR1 antibody. 
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Figure 36: Mixed BL Tl -/- / BL T2 -/- Bone Marrow Transplants in KlBxN Arthritis. 
BLTlIBLT2 +/+ recipient mice reconstituted with BLTlIBLT2 +/+ bone marrow (+/+ D/ 
+/+ R),BLTlIBLT2 +/+ recipient mice reconstituted with 50% BLTI -/- and 50% BLT2 
-/- bone marrow (1 -/- / 2 -1- DI +1+ R), BLTlIBLT2 -/- recipient mice reconstituted with 
BLTl/BLT2 +1+ bone marrow (+1+ DI 112 -1- R) and BLTl/BLT2 -/- recipient mice 
reconstituted with 50% BLTI -1- and 50% BLT2 -/- bone marrow bone marrow (1 -1- / 2-
/- DI 112 -1- R were observed every 1-2 days for visual signs of arthritis. (aj The 
incidence of clinical disease is shown demonstrating +1+ DI +1+ R (blue), +/+ D/ 112 -/-
R (red), 1 -1- 1 2 -1- D/ +/+ R (pink) and 1 -/- 1 2 -1- DI 112 -1- R (green) mice. . Mice 
were considered to have disease when they reached a clinical score of 2. (bj Clinical 
score was determined as described in Methods 
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Figure 37: Change in Paw and Ankle Thickness of Mixed BLTI -/- and BLT2 -/-
Bone Marrow Transplant Mice in KlBxN Arthritis. +/+ DI +/+ R (blue), 1 -/- / 2 -/-
D/ +1+ R (pink), +1+ D/ 1/2 -/- R (red) and 1 -/- / 2 -/- DI 112 -/- R (green) mice were 
followed every 1-2 days for increases in paw (a) and ankle (b) thickness using a dial 
pocket thickness gauge. 
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DISCUSSION 
Previous data from our laboratory showed that mIce deficient III BLTI or 
BL TlIBL T2 are completely protected from CIA on the C57Bl/6 background. 
BL TlIBLT2 +/- mice displayed a delay in the onset and a lower incidence of disease, but 
those mice that got disease had close to the same level of disease as wild-type mice. The 
data presented in this thesis confirm all the previous findings of an essential role for 
BLTI in murine arthritis. More importantly, they provide the first direct evidence for a 
biological activity associated with BL T2 because targeted disruption of BL T2 led to a 
complete protection against the development of serum transfer inflammatory arthritis. 
BL Tl is Critical for Arthritis Development 
A large body of data accumulated over the last decade has implicated L TB4 in 
arthritis. Despite persistent efforts from the pharmaceutical industry, no clear 
therapeutics targeting this pathway are available for arthritis. The current experiments 
showed complete protection of BLTI-/- mice against development of arthritis the DBAIl 
background for CIA. The BLTI +/- mice are delayed in incidence of disease compared 
to wild-type littermates. They do reach 100% incidence by the end of the experiment, but 
even at that time-point, the clinical score was significantly reduced compared to the wild-
type mice (p< 0.05). Measurement of the thickness of both the paw and ankle 
demonstrated a direct measure of the inflammation seen in these mice and once again, a 
delay in thickness is seen in the BLTI +/- mice in both the paw and ankle. In all these 
parameters, BLTI-/- mice were greatly protected showing very minimal signs of disease 
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in one mouse only. These data confirm that loss of BLTI protects mice from collagen 
induced arthritis regardless of the background of the mice. It is also in agreement with 
the BLTI antagonist study presented by Griffiths et al. in which they showed the 
antagonist CP-I05,696 was almost completely effective in blocking clinical signs of 
disease (154). When they gave the mice an injection of IL-l to accelerate the disease, 
they saw a significant increase in disease severity in the mice treated with the lower 
concentration of antagonist and a small increase in the animals treated with the higher 
concentration of antagonist (157). Subsequent publications all used accelerated arthritis 
models and only saw partial protection from arthritis. When two other antagonists, 
L Y293111 Na and CGS25019C, were used in an accelerated model of CIA, the decrease 
was not as significant as the previous study (only 38% reduced) (155). It is entirely 
possible that the antagonists used in Kuwabara et al. were not as efficacious as CP-
105,696. However, the fact that CP-I05,696 was almost completely protective in those 
experiments until IL-l was given to boost the mice demonstrates one simple point. BL Tl 
antagonism works well to block disease in non-accelerated CIA and IL-l acceleration 
results in an inflammatory process that is not completely blocked by BLTI antagonism. 
A straight-forward reason could be increased production of L TB4 in the synovium 
beyond the point where CP-I05,696 or the other antagonists are effective. In fact, when 
Kuwabara et al. tested the levels of L TB4 in the paws of these mice with and without the 
IL-l acceleration, they saw a significant increase in L TB4 levels in the IL-l accelerated 
mice over saline injected CIA mice at 6 hours (155). When they checked the LTB4 leveis 
at 24 hours, IL-l accelerated mice had 3X the levels of L TB4 in the paw than saline 
injected CIA mice. It is logical to suggest that if the levels of L TB4 in a mouse triple, 
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that the same amount of BL Tl antagonist would not be as effective. Another possible 
explanation for reduced effectiveness of BLTI antagonists in IL-l accelerated CIA 
models is that at high concentrations of L TB4, maintenance of arthritis in these mice 
could be switched to BLT2 (see below). In this case, while a strong BLTI inhibitor 
would work at initiation steps, once disease is initiated it might be more dependent on 
BLT2. In the same study, they also found increased levels of prostaglandin E2 (PGE2) in 
IL-l accelerated paws over saline controls. PGE2 is an inflammatory molecule and could 
explain this increase in clinical disease also. In an IL-18 accelerated CIA protocol, a 5-
LO inhibitor was shown effective in lowering the severity of disease, while it did not 
lower disease incidence by any significant level (99). Again in these experiments, if 5-
LO is activated by accelerated arthritis, then the inhibitor of 5-LO would not be nearly as 
effective in blocking activity. When both the BLTI antagonists and 5-LO antagonists 
were used in the KlBxN model which is not an accelerated disease, they were capable of 
almost entirely eliminating signs of disease. Thus, previous findings of effective 
inhibition of murine arthritis by BL Tl antagonists but clinical failure of the same 
inhibitors as arthritis treatment will have to be reexamined in relapsing and remitting type 
models of arthritis, similar to the EIA models. Unfortunately no such models are 
currently available and further experimentation might have to rely on repeated 
immunization or aggressive disease induction by cytokines like IL-l or use of repeated 
induction of disease with the serum transfer. 
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BL T2 is Critical for Serum Transfer Inflammatory Arthritis 
The KlBxN model of arthritis has proven to be useful in determining which cells 
are important in the effector phase of arthritis, by bypassing the steps of antigen 
processing and display of auto-reactive peptides on dendritic cells and T and B cell 
involvement. Having seen the result in CIA that BLTI -/- mice and BLTl/BLT2 -/- both 
were protected completely from disease development, we were not certain BL T2 played 
much of a role in arthritis. When we used BLT2 -/- mice in the KlBxN arthritis model, 
however, we found that these mice were almost completely protected from disease 
development. Very minimal signs of disease were noted with only one mouse showing 
disease in one leg. This finding was also visualized in sectioning of the ankle joint, 
where a large influx of inflammatory cells and bone destruction was seen in BLT2 +/+ 
sections, while little to no inflammation and bone destruction was seen in BLT2 -/-
sections. Our results also confirm the data of Kim et al. who saw a protection conferred 
by the loss of BLTI (158). We used our BLTI -/- mice in this experiment and also did 
not see any signs of disease in these mice either by macroscopic measures or in the 
analysis of ankle sections. Thus, there is an apparent non-redundant requirement for both 
BLTI and BL T2 in serum transfer-induced arthritis. 
Since the expression of BL T2 in mice is not clearly established, it was difficult to 
infer the cell type specificity of BLT2 expression required for induction of arthritis. To 
more fully understand this requirement, we performed reciprocal bone marrow transfer 
experiments between BLT2 +/+ and BLT2 -/- mice with a BLT2 +/+ mouse receiving 
BLT2 +/+ bone marrow serving as a positive control. Using this strategy, if the 
expression of BL T2 is critical on bone marrow-derived cells, then recipient mice which 
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receive BL T2 +/+ bone marrow will get disease whether they express BL T2 or not, thus 
making BLT2 -/- mice capable of developing arthritis and BLT2 +/+ mice unable to get 
arthritis. If the expression of BLT2 is required on non-bone marrow derived cells, then 
expression of BL T2 on the donor bone marrow would have no effect and BL T2 +/+ mice 
would get arthritis receiving BL T2 +/+ or BLT2 -/- bone marrow. To determine the 
extent of bone marrow engrafiment, we utilized C57B1I6.SJL BLT2 +/+ mice which 
carry the SJL CD45.1 marker, while our C57B1I6 BLT2-/- mice have the CD45.2 marker. 
Utilizing this strategy, we found that only about 2-5% of circulating neutrophils were 
derived from recipient bone marrow, which means 95-98% were produced from the 
donor bone marrow. This experiment demonstrated an absolute requirement for BL T2 on 
bone marrow-derived cells in arthritis induction. BL T2 +/+ and BLT2 -/- mice receiving 
BLT2 +/+ bone marrow both developed arthritis at similar levels. In fact, the BLT2 -/-
recipients consistently demonstrated slightly higher disease parameters than the BLT2 
+/+ recipients receiving BL T2+/+ marrow (positive control). BL T2 +/+ mice receiving 
BLT2 -/- bone marrow were protected from development of arthritis indicating absolutely 
no role for BL T2 on non-bone marrow-derived cells in arthritis development. 
Histopathological examination revealed massive inflammatory cell influx in the BLT2-/-
mice receiving BL T2+/+ marrow. Since both of these mice express similar levels of 
BLTI, it is clear that expression of BLTI alone in BLT2-/- mice is not sufficient for 
arthritis induction. 
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Induction of Arthritis in BL TIIBL T2-/- mice with bone marrow reconstitution from 
both BL Tl -/- and BL T2 -/- deficient mice 
We and others have shown that BLTI-/- mice do not develop arthritis in the 
KlBxN model. The data from Kim et al suggest that this is at least in part due to the fact 
that BL Tl must be present on neutrophils at early time-points, but is not necessary at 
later time points (158). One could hypothesize that BL Tl is absolutely necessary on 
neutrophils to initiate disease pathology. Data from Chen et al. suggested that 
neutrophils are the main source of L TB4 production in the synovium once they arrive 
(151). This potentially leads to an accumulation of LTB4 to a level at which effectual 
chemotaxis of neutrophils is not possible through BL Tl. In this case, BL T2 could be the 
chemotactic receptor to sense these higher concentrations of L TB4 at the site such that 
BLTI is no longer necessary. Indeed, we showed above that BLT2-/- mice are protected 
from development of arthritis. BLTlIBLT2 -/- mice should not develop KlBxN arthritis 
given the results seen with the single knockout mice and the fact that BL Tl/BLT2 -/-
mice did not develop CIA (21). The question we sought to answer was if we reconstitute 
a BLTl/BLT2 -/- mouse with both BLTI -/- BLT2 +/+ bone marrow and BLTI +/+ 
BLT2 -/- bone marrow, could the presence of BL Tl in a portion of neutrophils and BLT2 
on the remainder of the neutrophils lead to disease development? In other words, does 
expression of BLTI and BLT2 on separate cells induce arthritis in a mouse that lacks 
both receptors? 
To answer this question, we lethally irradiated both BL TlIBL T2 +/+ and 
BLTl/BLT2 -/- mice and reconstituted them with either BL TIIBLT2 +/+ bone marrow or 
an equal mixture ofBLTl -/- and BLT2 -1- bone marrow. After checking a blood sample 
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for CD45 subtype expression, the mice with the best engraftment were taken through the 
KlBxN model of arthritis. BL TlIBLT2 +/+ mice reconstituted with BLTlIBLT2 +/+ 
bone marrow demonstrated a rapid progression of disease as seen in the paw and ankle 
thickness and clinical score. BLTlIBLT2 -/- mice reconstituted with BLTlIBLT2 +/+ 
bone marrow reached similar levels of disease as BLTl/BLT2 +/+ recipients, but the 
kinetics of the disease process were slowed by a few days. We then demonstrated above 
that BLT2 +/+ mice reconstituted with BLT2 -/- bone marrow did not develop arthritis. A 
control group ofBL TlIBLT2 +/+ mice was reconstituted with BLTI -/- bone marrow and 
these mice also did not develop any major signs of arthritis. Reconstituting BLTIIBLT2 
+/+ and BLTl/BLT2 -/- mice with a mixture of both knock-out mouse bone marrow, 
however, led to an increase in signs of arthritis over reconstitution with either single 
knock-out bone marrow. Both BLTlIBLT2 +/+ and BLTlIBLT2 -/- recipients showed 
an increase in ankle thickness, clinical score and incidence over time with BLTl/BLT2 -
/- recipients showing more of an increase in clinical score and incidence than that of 
BL Tl/BL T2 +/+ recipients. Though the recipient mice did not get a wild-type level of 
arthritis when reconstituted with a mixture of BL Tl -/- and BLT2 -/- bone marrow, there 
is an undeniable increase in signs of arthritis. One possible explanation for this result is 
that BL Tl and BL T2 have to be found on the same cell for full disease progression. Kim 
et al. demonstrated a definite increase in disease parameters when BLTI -/- mice were 
reconstituted with BLTI +/+ neutrophils, but the level of the increase in ankle thickness 
and clinical score was about half of the level seen in BLTI +/+ mice (158). This is 
similar to the level of disease that was seen in our BLTI -/- and BLT2 -/- bone marrow 
mixture experiment. Since the coding regions of BLTI and BLT2 are so close on the 
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chromosome and the promoter for BLTI is found in the coding region of BLT2, it is 
possible that the two receptors could regulate one another and this is the reason BLTI 
and BL T2 expression on separate cells is not enough to develop full disease, but still 
produce enough inflammation for partial disease progression. 
In summary, the results presented here suggest a novel and unexpected role for 
the low affinity LTB4 receptor, BLT2, in arthritis. This result could explain, at least in 
part, the failure of many clinical trials using specific antagonists for the high affinity 
BLTI receptor. Targeting both LTB4 receptors with highly specific dual inhibitors might 
offer an attractive treatment option for human RA. 
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